{
  "questions": [
    {
      "body": "Which enhancers are characterized as latent?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23332752"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Latent enhancers are defined as regions of the genome that in terminally differentiated cells are unbound by TFs and lack the histone marks characteristic of enhancers but acquire these features in response to stimulation.", 
        "Here, we describe latent enhancers, defined as regions of the genome that in terminally differentiated cells are unbound by TFs", 
        "Here, we describe latent enhancers, defined as regions of the genome that in terminally differentiated cells are unbound by TFs and lack the histone marks characteristic of enhancers but acquire these features in response to stimulation.", 
        "here, we describe latent enhancers, defined as regions of the genome that in terminally differentiated cells are unbound by tfs and lack the histone marks characteristic of enhancers but acquire these features in response to stimulation.", 
        "Here , we describe latent enhancers , defined as regions of the genome that in terminally differentiated cells are unbound by TFs and lack the histone marks characteristic of enhancers but acquire these features in response to stimulation ."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "5ca60a77ecadf2e73f00004d", 
      "snippets": [
        {
          "offsetInBeginSection": 368, 
          "offsetInEndSection": 606, 
          "text": "Here, we describe latent enhancers, defined as regions of the genome that in terminally differentiated cells are unbound by TFs and lack the histone marks characteristic of enhancers but acquire these features in response to stimulation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23332752", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 368, 
          "offsetInEndSection": 605, 
          "text": "Here, we describe latent enhancers, defined as regions of the genome that in terminally differentiated cells are unbound by TFs and lack the histone marks characteristic of enhancers but acquire these features in response to stimulation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23332752", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 66, 
          "text": "Latent enhancers activated by stimulation in differentiated cells.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23332752", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What is the difference between COG133 and COG112?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16740622"
      ], 
      "triples": [], 
      "ideal_answer": [
        "COG112 results from the fusion of COG133 to a protein transduction domain."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "5c88b8a275a4a5d21900000b", 
      "snippets": [
        {
          "offsetInBeginSection": 728, 
          "offsetInEndSection": 1017, 
          "text": "Most notably, fusion of COG133 to a protein transduction domain creates COG112, a modified apoE-mimetic peptide with significantly enhanced anti-inflammatory bioactivities in vitro, and improved therapeutic effects on EAE in vivo, which renders a nearly full remission from the disability.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16740622", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Velocardial facial syndrome, otherwise known as Di George syndrome  is caused by a deletion in chromosome 21, yes or no?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/15734119", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16617304", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9674897", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26605035", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8998528", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12238021", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25523123"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Velocardial facial syndrome, otherwise known as Di George syndrome is caused by a deletion in chromosome 22.", 
        "The deletion of chromosome 22q11.2 is involved in the majority of DiGeorge or velo-cardiofacial syndrome."
      ], 
      "exact_answer": "no", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5c97a08becadf2e73f000029", 
      "snippets": [
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 117, 
          "text": "The deletion of chromosome 22q11.2 is involved in the majority of DiGeorge or velo-cardiofacial syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15734119", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 315, 
          "offsetInEndSection": 451, 
          "text": "deletions of chromosome 7q11.23 (Williams syndrome), 15q11-q13 (Angelman syndrome, Prader-Willi syndrome) and 22q11 (Di George syndrome)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16617304", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 201, 
          "text": "Submicroscopic deletions of chromosome 22q11 have been reported in a multiple anomaly syndrome variously labelled as velocardiofacial syndrome, conotruncal anomaly face syndrome, and Di George syndrome", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9674897", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 98, 
          "text": "The 22q11.2 deletion syndrome (di George syndrome) is one of the most prevalent genetic disorders.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26605035", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 155, 
          "text": "UNLABELLED\nMost of the children with Di George syndrome and 60% of patients with velocardiofacial syndrome exhibit a microdeletion within chromosome 22q11.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8998528", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 202, 
          "text": "Submicroscopic deletions of chromosome 22q11 have been reported in a multiple anomaly syndrome variously labelled as velocardiofacial syndrome, conotruncal anomaly face syndrome, and Di George syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9674897", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 112, 
          "offsetInEndSection": 364, 
          "text": "22q11.2DS has several presentations including Di George's syndrome, velo-cardio-facial syndrome or Shprintzen's syndrome and it is the most frequent microdeletion syndrome in the general population (prevalence estimated at 1/4000 births, de novo: 90%).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25523123", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1088, 
          "offsetInEndSection": 1580, 
          "text": "Di George syndrome due to mutation on 22q or 10q) and can also result from microdeletion or point mutation (in the Shprintzen syndrome 70% represent microdeletion and 30% point mutation at 22q11, in Rubinstein-Taybi syndrome 10% cases result from microdeletions and 90% from point mutations); 7) Population incidence of microdeletions is high (1:4000 to 1:30,000) because their etiologic mechanism is related to the common unequal crossing over; 8) Imprinting plays a role in some cases, e.g.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12238021", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 265, 
          "text": "[Microdeletion of the chromosome 22q11 in children: apropos of a series of 49 patients].<AbstractText Label=\"UNLABELLED\">Most of the children with Di George syndrome and 60% of patients with velocardiofacial syndrome exhibit a microdeletion within chromosome 22q11. ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8998528", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 236, 
          "offsetInEndSection": 488, 
          "text": "22q11.2DS has several presentations including Di George's syndrome, velo-cardio-facial syndrome or Shprintzen's syndrome and it is the most frequent microdeletion syndrome in the general population (prevalence estimated at 1/4000 births, de novo: 90%). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25523123", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 163, 
          "text": "<b>UNLABELLED</b>: Most of the children with Di George syndrome and 60% of patients with velocardiofacial syndrome exhibit a microdeletion within chromosome 22q11.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8998528", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 144, 
          "text": "Most of the children with Di George syndrome and 60% of patients with velocardiofacial syndrome exhibit a microdeletion within chromosome 22q11.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8998528", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is the protein Asporin related to disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28152543", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27705916", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27409832", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25689697"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes,\nAccumulating evidence demonstrates the involvement of asporin in OA pathogenesis. Asporin has been reported as a tumor suppressor in breast cancer, while asporin-activated invasion has been described in gastric cancer."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5c8ab614d558e5f23200000d", 
      "snippets": [
        {
          "offsetInBeginSection": 307, 
          "offsetInEndSection": 388, 
          "text": "Accumulating evidence demonstrates the involvement of asporin in OA pathogenesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25689697", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 136, 
          "text": "Asporin has been reported as a tumor suppressor in breast cancer, while asporin-activated invasion has been described in gastric cancer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27409832", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 78, 
          "text": "Asporin has been implicated as an oncogene in various types of human cancers; ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27705916", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1264, 
          "offsetInEndSection": 1425, 
          "text": " These results suggested that asporin promoted the tumor growth and metastasis of CRC, and it could be a potential therapeutic target for CRC patients in future.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27705916", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1975, 
          "offsetInEndSection": 2118, 
          "text": "Our results suggest that ASPN is a stromally expressed biomarker that correlates with disease progression, and is observed in reactive stroma. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28152543", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can TAD disruption lead to disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29990539", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30241613", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28408976", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26862051", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27111891", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30086749", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30374058", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25959774", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22495304"
      ], 
      "triples": [], 
      "ideal_answer": [
        "TAD boundaries are insulators of genomic neighborhoods. \u03a4he disruption of these structures by genomic rearrangements can result in gene misexpression and disease.", 
        "We discuss how the disruption of these structures by genomic rearrangements can result in gene misexpression and disease."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5ca61176ecadf2e73f00004e", 
      "snippets": [
        {
          "offsetInBeginSection": 695, 
          "offsetInEndSection": 954, 
          "text": "its perturbation will lead to human disease, highlighting the accumulating evidence that links the diverse 3D genome architecture components to a multitude of human diseases and the emerging mechanisms by which 3D genome derangement causes disease phenotypes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29990539", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 185, 
          "text": "TAD boundaries are insulators of genomic neighborhoods. In this issue, Sun et\u00a0al. show that disease-associated tandem repeats are located to TAD boundaries and affect their insulation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30241613", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 552, 
          "offsetInEndSection": 773, 
          "text": "Recent studies of TAD boundaries disrupted in engineered mouse models show that boundary mutations can recapitulate human developmental disorders as a result of aberrant promoter-enhancer interactions in the affected TADs", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28408976", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 775, 
          "offsetInEndSection": 941, 
          "text": "Similar boundary disruptions in certain cancers can result in oncogene overexpression, and CTCF binding sites at boundaries appear to be hyper-mutated across cancers.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28408976", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 440, 
          "offsetInEndSection": 546, 
          "text": "the disruption of these structures by genomic rearrangements can result in gene misexpression and disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26862051", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 35, 
          "text": "TAD disruption as oncogenic driver.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27111891", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 278, 
          "offsetInEndSection": 409, 
          "text": "Recent studies have shown that TAD disruption is often found in cancer cells and contributes to oncogenesis through two mechanisms.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27111891", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 157, 
          "offsetInEndSection": 277, 
          "text": "Disruption of TAD boundaries results in aberrant gene expression by exposing genes to inappropriate regulatory elements.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27111891", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 457, 
          "offsetInEndSection": 625, 
          "text": "However, it is not clear to which extent TAD regions are conserved in evolution and whether disruption of TADs by evolutionary rearrangements can alter gene expression.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30086749", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 239, 
          "offsetInEndSection": 409, 
          "text": "Disruption of this organization by structural variations can lead to ectopic interactions between enhancers and promoters, and to alteration of genes expression patterns.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30374058", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 349, 
          "offsetInEndSection": 456, 
          "text": "Disruption of TADs can result in altered gene expression and is associated to genetic diseases and cancers.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30086749", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 129, 
          "text": "Deletion in 2q35 excluding the IHH gene leads to fetal severe limb anomalies and suggests a disruption of chromatin architecture.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30374058", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 194, 
          "offsetInEndSection": 315, 
          "text": "We demonstrate that disruption of TADs can rewire long-range regulatory architecture and result in pathogenic phenotypes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25959774", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 192, 
          "offsetInEndSection": 312, 
          "text": "Disruption of TAD boundaries results in aberrant gene expression by exposing genes to inappropriate regulatory elements. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27111891", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 476, 
          "offsetInEndSection": 583, 
          "text": "Disruption of TADs can result in altered gene expression and is associated to genetic diseases and cancers. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30086749", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1077, 
          "offsetInEndSection": 1187, 
          "text": "Disruption of a TAD boundary causes ectopic chromosomal contacts and long-range transcriptional misregulation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22495304", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 632, 
          "offsetInEndSection": 854, 
          "text": "Recent studies of TAD boundaries disrupted in engineered mouse models show that boundary mutations can recapitulate human developmental disorders as a result of aberrant promoter-enhancer interactions in the affected TADs. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28408976", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 313, 
          "offsetInEndSection": 444, 
          "text": "Recent studies have shown that TAD disruption is often found in cancer cells and contributes to oncogenesis through two mechanisms. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27111891", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 368, 
          "offsetInEndSection": 538, 
          "text": "Disruption of this organization by structural variations can lead to ectopic interactions between enhancers and promoters, and to alteration of genes expression patterns. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30374058", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 855, 
          "offsetInEndSection": 1021, 
          "text": "Similar boundary disruptions in certain cancers can result in oncogene overexpression, and CTCF binding sites at boundaries appear to be hyper-mutated across cancers. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28408976", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 584, 
          "offsetInEndSection": 752, 
          "text": "However, it is not clear to which extent TAD regions are conserved in evolution and whether disruption of TADs by evolutionary rearrangements can alter gene expression. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30086749", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is L-4F an apoE mimetic peptide?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29245934"
      ], 
      "triples": [], 
      "ideal_answer": [
        "No, L-4F is an apoA-I mimetic peptide."
      ], 
      "exact_answer": "no", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5c8908a475a4a5d21900000c", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 112, 
          "text": "Apolipoprotein A-I mimetic peptide 4F suppresses tumor-associated macrophages and pancreatic cancer progression.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29245934", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 193, 
          "offsetInEndSection": 337, 
          "text": "L-4F, an Apolipoprotein A-I (ApoA-I) mimetic peptide, is engineered to mimic the anti-inflammatory and anti-oxidative functionalities of ApoA-I.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29245934", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which cells secrete lactotransferrin?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24561791"
      ], 
      "triples": [], 
      "ideal_answer": [
        "We conclude that lactotransferrin represents a late stage differentiation marker of neutrophils, macrophages and distinct subtypes of dendritic cells."
      ], 
      "exact_answer": [
        [
          "neutrophils"
        ], 
        [
          "macrophages"
        ], 
        [
          "dendritic"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "5c8c095e0101eac870000002", 
      "snippets": [
        {
          "offsetInBeginSection": 1243, 
          "offsetInEndSection": 1393, 
          "text": "We conclude that lactotransferrin represents a late stage differentiation marker of neutrophils, macrophages and distinct subtypes of dendritic cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24561791", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which plant does oleuropein originate from?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29099642"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Oleuropein originates from olive trees, and is specifically found in olive leaf extracts."
      ], 
      "exact_answer": [
        [
          "Olive tree"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c890ad575a4a5d21900000d", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 88, 
          "text": "Oleuropein Is Responsible for the Major Anti-Inflammatory Effects of Olive Leaf Extract.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29099642", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 745, 
          "offsetInEndSection": 854, 
          "text": "Oleuropein is the only OLE component that has shown anti-inflammatory effects at a concentration of 20\u2009\u03bcg/mL.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29099642", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1015, 
          "offsetInEndSection": 1242, 
          "text": "Downregulation of TNF\u03b1 secretion in PMNCs culture in response to OLE treatment indicates that this polyphenol-rich extract has an anti-inflammatory effect, and oleuropein is the major OLE component responsible for this effect. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29099642", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Reslizumab is a humanized monoclonal antibody to treat what specific type of asthma?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29059618", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29486600", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29554826", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30346831", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28683596", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28421429", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28344579", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27445482", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23326187", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27458609"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Reslizumab is a humanized monoclonal antibody to treat eosinophilic asthma", 
        "Reslizumab in the treatment of severe eosinophilic asthma:\u00a0an update."
      ], 
      "exact_answer": [
        [
          "eosinophilic asthma"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5ca0bf00ecadf2e73f000045", 
      "snippets": [
        {
          "offsetInBeginSection": 131, 
          "offsetInEndSection": 398, 
          "text": "Since IL-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting IL-5/IL-5R\u03b1 have been developed and/or marketed, including Mepolizumab, Reslizumab, and Benralizumab.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29059618", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 14, 
          "offsetInEndSection": 383, 
          "text": "Reslizumab, a humanized mAb against IL-5, reduces the number of eosinophils in the blood and lungs. Based on efficacy and safety data from pivotal RCTs, reslizumab had been approved for use as an add-on maintenance treatment of severe asthma with an eosinophilic phenotype in adults who have a history of exacerbations despite receiving their current asthma medicines. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29486600", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 57, 
          "text": "Reslizumab in the treatment of severe eosinophilic asthma", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29554826", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 311, 
          "offsetInEndSection": 547, 
          "text": "Reslizumab is a humanized monoclonal (immunoglobulin G4/\u03ba) antibody that binds with high affinity to circulating human IL-5 and downregulates the IL-5 signaling pathway, potentially disrupting the maturation and survival of eosinophils.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683596", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 154, 
          "text": "Reslizumab (Cinqaero\u00ae; Cinqair\u00ae) is a humanized monoclonal antibody against interleukin-5 (IL-5), a cytokine mediator of eosinophilic airway inflammation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28421429", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 164, 
          "text": "BACKGROUND\nReslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30346831", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 522, 
          "offsetInEndSection": 920, 
          "text": "In particular, reslizumab is a humanized anti-IL-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27445482", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 297, 
          "offsetInEndSection": 483, 
          "text": "Reslizumab (Cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23326187", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 155, 
          "offsetInEndSection": 316, 
          "text": "Reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the BREATH phase III clinical trial programme.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28421429", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 220, 
          "text": "Reslizumab in Eosinophilic Asthma: A Review.Reslizumab (Cinqaero<sup>\u00ae</sup>; Cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (IL-5), a cytokine mediator of eosinophilic airway inflammation. ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28421429", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 477, 
          "offsetInEndSection": 713, 
          "text": "Reslizumab is a humanized monoclonal (immunoglobulin G4/\u03ba) antibody that binds with high affinity to circulating human IL-5 and downregulates the IL-5 signaling pathway, potentially disrupting the maturation and survival of eosinophils. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683596", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 419, 
          "offsetInEndSection": 605, 
          "text": "Reslizumab (Cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23326187", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 101, 
          "text": "Reslizumab: Maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27458609", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What is the function of the protein Magt1?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29581357", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30385806", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29051561"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The magnesium transporter 1 (MAGT1) is a critical regulator of basal intracellular free magnesium ([Mg2+]i) levels."
      ], 
      "exact_answer": [
        [
          "Magnesium transporter"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c92869aecadf2e73f000015", 
      "snippets": [
        {
          "offsetInBeginSection": 162, 
          "offsetInEndSection": 193, 
          "text": "magnesium transporter 1 (MAGT1)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29581357", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 217, 
          "offsetInEndSection": 244, 
          "text": "magnesium transporter MagT1", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30385806", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "The magnesium transporter 1 (MAGT1) is a critical regulator of basal intracellular free magnesium ([Mg2+]i) levels. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29051561", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can oleuropein aglycone interfere with amyloid aggregation?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29571746"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes, oleuropein aglycone interferes in vitro and in vivo with amyloid aggregates."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5c890c3375a4a5d21900000e", 
      "snippets": [
        {
          "offsetInBeginSection": 285, 
          "offsetInEndSection": 684, 
          "text": "Oleuropein, a phenolic secoiroid glycoside, is the main polyphenol in the olive oil. It has been reported that the aglycone form of Oleuropein (OleA) interferes in vitro and in vivo with amyloid aggregation of a number of proteins/peptides involved in amyloid, particularly neurodegenerative, diseases avoiding the growth of toxic oligomers and displaying protection against cognitive deterioration.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29571746", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the function of the transcriptional co-activator p300?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30323286", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23211718"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The transcriptional co-activator p300 is a histone acetyltransferase (HAT) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin."
      ], 
      "exact_answer": [
        [
          "histone acetyltransferase"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c990241ecadf2e73f00002d", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 187, 
          "text": "The transcriptional co-activator p300 is a histone acetyltransferase (HAT) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30323286", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 232, 
          "text": "p300, a transcriptional co-activator with histone acetyl transferase (HAT) activity, plays an essential role in the pathogenesis of cardiomyocyte hypertrophy in response to multiple pro-hypertrophic stimuli including hyperglycemia. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23211718", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is another name for the plant Sideritis scardica?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22274814"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Sideritis scardica is also known as ironwort or mountain tea."
      ], 
      "exact_answer": [
        [
          "Mountain tea", 
          "Ironwort"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c890e6d75a4a5d21900000f", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 221, 
          "text": "Sideritis scardica Griseb. (ironwort, mountain tea), an endemic plant of the Balkan Peninsula, has been used in traditional medicine in the treatment of gastrointestinal complaints, inflammation, and rheumatic disorders. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22274814", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "How are gas vesicle proteins used in imaging?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28956265", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29483636", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27351374", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28880278"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Gas vesicles (GVs)-a unique class of gas-filled protein nanostructures-have recently been introduced as a promising new class of ultrasound contrast agents.", 
        "Gas vesicles (GVs)-a unique class of gas-filled protein nanostructures-have recently been introduced as a promising new class of ultrasound contrast agents that can potentially access the extravascular space and be modified for molecular targeting.", 
        "Gas vesicles (GVs)-a unique class of gas-filled protein nanostructures-have recently been introduced as a promising new class of ultrasound contrast agents that can potentially access the extravascular space and be modified for molecular targeting"
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "5ca9f5e4ecadf2e73f000052", 
      "snippets": [
        {
          "offsetInBeginSection": 217, 
          "offsetInEndSection": 466, 
          "text": "Gas vesicles (GVs)-a unique class of gas-filled protein nanostructures-have recently been introduced as a promising new class of ultrasound contrast agents that can potentially access the extravascular space and be modified for molecular targeting. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28956265", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 153, 
          "offsetInEndSection": 402, 
          "text": "Here, we show that gas vesicles (GVs), a unique class of gas-filled protein nanostructures with differential magnetic susceptibility relative to water, can produce robust contrast in magnetic resonance imaging (MRI) at sub-nanomolar concentrations, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29483636", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 234, 
          "text": "Gas vesicles (GVs) are a unique class of gas-filled protein nanostructures that are detectable at subnanomolar concentrations and whose physical properties allow them to serve as highly sensitive imaging agents for ultrasound and MRI.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28880278", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 101, 
          "text": "Preparation of biogenic gas vesicle nanostructures for use as contrast agents for ultrasound and MRI.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28880278", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 774, 
          "offsetInEndSection": 1040, 
          "text": "Here, we demonstrate that genetic engineering of gas vesicles results in nanostructures with new mechanical, acoustic, surface, and functional properties to enable harmonic, multiplexed, and multimodal ultrasound imaging as well as cell-specific molecular targeting.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27351374", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 153, 
          "offsetInEndSection": 502, 
          "text": "Here, we show that gas vesicles (GVs), a unique class of gas-filled protein nanostructures with differential magnetic susceptibility relative to water, can produce robust contrast in magnetic resonance imaging (MRI) at sub-nanomolar concentrations, and that this contrast can be inactivated with ultrasound in situ to enable background-free imaging.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29483636", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "From where is gamabufotalin (GBT) isolated?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30111043", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28631214", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26894970", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25175164"
      ], 
      "triples": [], 
      "ideal_answer": [ "gamabufotalin (GBT) was isolated from toad venom."], 
      "exact_answer": [
        [
          "toad venom"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c9904eaecadf2e73f00002e", 
      "snippets": [
        {
          "offsetInBeginSection": 1219, 
          "offsetInEndSection": 1610, 
          "text": "RCFs of cinobufagin to gamabufotalin, bufotalin, bufalin and resibufogenin were determined as 1.05, 0.895, 1.09 and 0.913, respectively. The characteristic chromatogram and QAMS established in this study could effectively control the quality of toad venom and provide scientific evidence for the improvement of the quality standard of the toad venom to be described in Chinese Pharmacopoeia ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30111043", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 117, 
          "offsetInEndSection": 249, 
          "text": "We identified three bufadienolides-the steroid-like compounds arenobufagin, gamabufotalin, and telocinobufagin-from the boreal toad,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28631214", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 165, 
          "offsetInEndSection": 235, 
          "text": "In the current study, gamabufotalin (GBT) was isolated from toad venom", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26894970", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 55, 
          "text": "Gamabufotalin, a bufadienolide compound from toad venom", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25175164", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What are super-enhancers", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29754476"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Super-enhancers are large clusters of enhancers covering the long region of regulatory DNA and are densely occupied by transcription factors, active histone marks, and co-activators. Accumulating evidence points to the critical role that super-enhancers play in cell type-specific development and differentiation, as well as in the development of various diseases."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "5c895e5ef9c2ba6b28000002", 
      "snippets": [
        {
          "offsetInBeginSection": 355, 
          "offsetInEndSection": 719, 
          "text": "Super-enhancers are large clusters of enhancers covering the long region of regulatory DNA and are densely occupied by transcription factors, active histone marks, and co-activators. Accumulating evidence points to the critical role that super-enhancers play in cell type-specific development and differentiation, as well as in the development of various diseases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29754476", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is Apelin usually decreased in diabetes?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29229313", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25914650", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24721640", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19756893"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Different studies in both animals and humans have shown that plasma apelin concentrations are usually increased during obesity and type 2 diabetes."
      ], 
      "exact_answer": "no", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5caa0806ecadf2e73f000057", 
      "snippets": [
        {
          "offsetInBeginSection": 558, 
          "offsetInEndSection": 816, 
          "text": "Apelin has been shown to act on glucose and lipid metabolism but also to modulate insulin secretion. Moreover, different studies in both animals and humans have shown that plasma apelin concentrations are usually increased during obesity and type 2 diabetes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25914650", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 630, 
          "offsetInEndSection": 791, 
          "text": "Upregulated expression of resistin, vaspin, apelin and TNF-\u03b1 plays a significant role in induction of insulin resistance linked with obesity and type 2 diabetes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29229313", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 659, 
          "offsetInEndSection": 816, 
          "text": "Moreover, different studies in both animals and humans have shown that plasma apelin concentrations are usually increased during obesity and type 2 diabetes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25914650", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 85, 
          "text": "Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19756893", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1217, 
          "offsetInEndSection": 1593, 
          "text": "In men at risk for diabetes (HbA1c 5.7-6.4%, FPG 100-125mg/dl, or OGTT-2h-PG 140-199mg/dl), the risk for developing diabetes was higher in those with higher plasma apelin concentration than in those with lower plasma apelin concentrations (10.6%/year vs. 5.1%/year, p<0.001).<br><b>CONCLUSIONS</b>: Plasma apelin is a novel biomarker for predicting type 2 diabetes in men.<br>", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24721640", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is a mitosome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30265292", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28372543", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21984067", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20382757"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Mitosomes are the simplest and the least well-studied type of anaerobic mitochondria. \tThe mitosomes have abandoned typical mitochondrial traits such as the mitochondrial genome and aerobic respiration and their single role known to date is the formation of iron-sulfur clusters"
      ], 
      "exact_answer": [
        [
          "Simple and anaerobic mitochondria."
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c9a6693ecadf2e73f000031", 
      "snippets": [
        {
          "offsetInBeginSection": 93, 
          "offsetInEndSection": 179, 
          "text": "Mitosomes are the simplest and the least well-studied type of anaerobic mitochondria. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30265292", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 301, 
          "offsetInEndSection": 492, 
          "text": "The mitosomes have abandoned typical mitochondrial traits such as the mitochondrial genome and aerobic respiration and their single role known to date is the formation of iron-sulfur clusters", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28372543", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 59, 
          "offsetInEndSection": 138, 
          "text": "a mitosome, a relict mitochondrion with a greatly reduced metabolic capability.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21984067", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 226, 
          "offsetInEndSection": 421, 
          "text": "he highly divergent mitochondrion-related organelle, the mitosome, in the anaerobic/microaerophilic protozoan parasite Entamoeba histolytica based on the potential mitochondrion-targeting signal.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20382757", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the price of KYMRIAH treatment in 2019?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29764166"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Kymriah, produced by Novartis has a price tag of US$475,000."
      ], 
      "exact_answer": [
        [
          "475,000 USD"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c897082d558e5f232000004", 
      "snippets": [
        {
          "offsetInBeginSection": 284, 
          "offsetInEndSection": 646, 
          "text": "At the time of the writing of this article, there are two CAR T cells available, Kymriah, produced by Novrtis with a price tag of US$475,000 and Yescarta produced by Gilead Pharmaceuticals with a price tag of US$373,000, neither price including the required hospital admission in order to administer the agent in addition to potential treatment of side effects. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29764166", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Human dihydroorotate dehydrogenase is a drug target and is involved in what biosynthetic pathway", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30145372", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30233375", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27481247", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30200251", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19351152", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20334617", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28666740", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17228860", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16172019", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18312275", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1348618", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25945707", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24900364", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27744189", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26088338", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22542640", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20702404", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18842591", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1617622", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2386542", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22580100"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Dihydroorotate dehydrogenase (DHODH) catalyzes the fourth reaction of the de novo pyrimidine biosynthetic pathway, which exerts vital functions in the cells, especially within DNA and RNA biosynthesis.", 
        "Dihydroorotate dehydrogenase (DHODH) mediates the fourth step of de novo pyrimidine biosynthesis", 
        "The flavoenzyme dihydroorotate dehydrogenase (DHODH) catalyzes the fourth reaction of the de novo pyrimidine biosynthetic pathway, which exerts vital functions in the cells, especially within DNA and RNA biosynthesis"
      ], 
      "exact_answer": [
        [
          "pyrimidine biosynthesis"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5cb0856decadf2e73f000058", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 218, 
          "text": "The flavoenzyme dihydroorotate dehydrogenase (DHODH) catalyzes the fourth reaction of the de novo pyrimidine biosynthetic pathway, which exerts vital functions in the cells, especially within DNA and RNA biosynthesis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30145372", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 103, 
          "text": "Human dihydroorotate dehydrogenase (HsDHODH) is a key enzyme of pyrimidine de novo biosynthesis pathway", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30233375", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 251, 
          "text": "Dihydroorotate dehydrogenase (DHODH) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27481247", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 651, 
          "offsetInEndSection": 858, 
          "text": "This review focuses on recent studies to exploit the fourth enzyme in the de novo pyrimidine biosynthetic pathway of P. falciparum, dihydroorotate dehydrogenase (PfDHODH), as a new target for drug discovery.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20334617", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 229, 
          "text": "The flavoenzyme dihydroorotate dehydrogenase catalyzes the stereoselective oxidation of (S)-dihydroorotate to orotate in the fourth of the six conserved enzymatic reactions involved in the de novo pyrimidine biosynthetic pathway.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28666740", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 132, 
          "offsetInEndSection": 283, 
          "text": "A set of compounds designed to inhibit the Plasmodium falciparum pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase (PfDHODH) was synthesized.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17228860", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 189, 
          "text": "Dihydroorotate dehydrogenase (DHOD) is the fourth enzyme in the de novo pyrimidine biosynthetic pathway and is essential in Trypanosoma cruzi, the parasitic protist causing Chagas' disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16172019", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 97, 
          "offsetInEndSection": 304, 
          "text": "Hence, we evaluated the essentiality of one enzyme in the pyrimidine biosynthetic pathway, dihydroorotate dehydrogenase (DHODH) from the eukaryotic parasite Trypanosoma brucei through gene knockdown studies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18312275", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 145, 
          "offsetInEndSection": 327, 
          "text": "Dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19351152", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 314, 
          "text": "Inhibition of dihydroorotate dehydrogenase (DHODH) for P. falciparum potentially represents a new treatment option for malaria, since DHODH catalyzes the rate-limiting step in the pyrimidine biosynthetic pathway and P. falciparum is unable to salvage pyrimidines and must rely on de novo biosynthesis for survival.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24900364", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 68, 
          "offsetInEndSection": 315, 
          "text": "An important target for antimalarial chemotherapy is the enzyme dihydroorotate dehydrogenase from Plasmodium falciparum (PfDHODH), which is responsible for the conversion of dihydroorotate to orotate in the de novo pyrimidine biosynthetic pathway.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27744189", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 273, 
          "offsetInEndSection": 453, 
          "text": "Dihydroorotate dehydrogenase (DHODH) is an enzyme in the pyrimidine biosynthetic pathway which is an important target for anti-hyperproliferative and anti-inflammatory drug design.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26088338", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 199, 
          "text": "Dihydroorotate dehydrogenase (DHODH) is the fourth enzyme in the de novo pyrimidine biosynthetic pathway and has been exploited as the target for therapy against proliferative and parasitic diseases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22542640", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 170, 
          "offsetInEndSection": 339, 
          "text": "Dihydroorotate dehydrogenase (DHODH) catalyzes the rate-limiting step in the pyrimidine biosynthetic pathway and represents a potential target for anti-malarial therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20702404", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 170, 
          "text": "The enzyme dihydroorotate dehydrogenase (DHODH) is a flavoenzyme that catalyses the oxidation of dihydroorotate to orotate in the de novo pyrimidine-biosynthesis pathway.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25945707", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 163, 
          "text": "Dihydroorotase and dihydroorotate dehydrogenase, two enzymes of the pyrimidine biosynthetic pathway, were purified from Plasmodium berghei to apparent homogeneity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1348618", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 215, 
          "offsetInEndSection": 410, 
          "text": "Dihydroorotate dehydrogenase (DHOD), a mitochondrially localized flavoenzyme, catalyzes the rate-limiting step of this pathway and is therefore an attractive antimalarial chemotherapeutic target.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18842591", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 104, 
          "text": "Human dihydroorotate dehydrogenase (HsDHODH) is a key enzyme of pyrimidine de novo biosynthesis pathway.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30233375", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 280, 
          "offsetInEndSection": 462, 
          "text": "Dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19351152", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 263, 
          "text": "Biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from Toxoplasma gondii.The pyrimidine biosynthesis pathway in the protozoan pathogen Toxoplasma gondii is essential for parasite growth during infection. ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22580100", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 748, 
          "offsetInEndSection": 955, 
          "text": "This review focuses on recent studies to exploit the fourth enzyme in the de novo pyrimidine biosynthetic pathway of P. falciparum, dihydroorotate dehydrogenase (PfDHODH), as a new target for drug discovery. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20334617", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 306, 
          "text": "The novel anticancer drug candidate brequinar sodium (DuP 785, NSC 368390, 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinoline- carboxylic acid sodium salt) was shown previously to be an inhibitor of dihydroorotate dehydrogenase, the fourth enzyme of the de novo pyrimidine biosynthetic pathway.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1617622", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 189, 
          "text": "Dihydroorotate dehydrogenase (DHODH), in the de novo pyrimidine biosynthetic pathway, is the fourth enzyme of pyrimidine synthesis and is used to oxidize dihydroorotate and hence to orotat.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30200251", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 303, 
          "text": "The novel anticancer drug candidate brequinar sodium [DuP 785, NSC 368390, 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinoline carboxylic acid sodium salt] inhibits dihydroorotate dehydrogenase, the fourth enzyme in the de novo pyrimidine biosynthetic pathway leading to the formation of UMP.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2386542", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List targets of classical analgesics.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20942817", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19474215"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Patient phenotypes in pharmacological pain treatment varies between individuals, which could be partly assigned to their genotypes regarding the targets of classical analgesics (OPRM1, PTGS2)"
      ], 
      "exact_answer": [
        [
          "OPRM1"
        ], 
        [
          "PTGS2"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "5c9d18f1ecadf2e73f000033", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 192, 
          "text": "Patient phenotypes in pharmacological pain treatment varies between individuals, which could be partly assigned to their genotypes regarding the targets of classical analgesics (OPRM1, PTGS2) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20942817", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 184, 
          "offsetInEndSection": 339, 
          "text": "Morphine is the current gold standard analgesic acting at MOP receptors but produces a range of variably troublesome side-effects, in particular tolerance.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19474215", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is actin present in the nucleus?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29568381", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29925947", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30019087", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30312531", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30193156"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes,\nThe revitalization of research into nuclear actin occurred after it was found that cellular stresses induce the nuclear localization and alter the structure of actin."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5ca0fdb0ecadf2e73f000049", 
      "snippets": [
        {
          "offsetInBeginSection": 641, 
          "offsetInEndSection": 812, 
          "text": "Moreover, inhibition of ATM kinase or deficiency in nuclear actin polymerization causes carcinogenic RET/PTC chromosome rearrangements after DSBs induction in human cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29568381", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1024, 
          "offsetInEndSection": 1209, 
          "text": " Our findings establish that nuclear actin-based mobility shapes chromatin organization by generating repair domains that are essential for homology-directed repair in eukaryotic cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29925947", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 579, 
          "offsetInEndSection": 751, 
          "text": "The discovery of nuclear actin opened new perspective on the field, suggesting that the nuclear activities of actin reflect the functions of primordial actin-like proteins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30019087", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 114, 
          "offsetInEndSection": 282, 
          "text": " The revitalization of research into nuclear actin occurred after it was found that cellular stresses induce the nuclear localization and alter the structure of actin. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30312531", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 190, 
          "text": "While it is long known that actin is part of the nuclear proteome, its properties and functions as regulated, functional and dynamically assembled actin filaments are only recently emerging.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30193156", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the indication for KYMRIAH?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29501911"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Kymriah\u2122 has been approved for the treatment of pediatric patients and young adults with refractory or relapse (R/R) B cell precursor acute lymphoblastic leukemia."
      ], 
      "exact_answer": [
        [
          "children and young adults with refractory or relapse B cell precursor acute lymphoblastic leukemia"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c896f60d558e5f232000003", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 357, 
          "text": "Two autologous chimeric antigen receptor (CAR) T cell therapies (Kymriah\u2122 and Yescarta\u2122) were recently approved by the FDA. Kymriah\u2122 is for the treatment of pediatric patients and young adults with refractory or relapse (R/R) B cell precursor acute lymphoblastic leukemia and Yescarta\u2122 is for the treatment of adult patients with R/R large B cell lymphoma. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29501911", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the effect of NFIA on astrocyte differentiation?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30290178"
      ], 
      "triples": [], 
      "ideal_answer": [
        "NFIA promotes astrocyte differentiation from neural precursor cells."
      ], 
      "exact_answer": [
        [
          "Promotes", 
          "Induces"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c8fe1f10101eac87000000a", 
      "snippets": [
        {
          "offsetInBeginSection": 647, 
          "offsetInEndSection": 857, 
          "text": "By searching for transcription factors that function at these elements, we identified NFIA and ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30290178", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the mode of action for Tocilizumab?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24729685", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27790001", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22101760"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody against the IL-6 receptor and has been approved in many countries, including the United States, for the treatment of moderate to severe RA in patients who have not adequately responded to one or more disease-modifying antirheumatic drugs"
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "5c960afaecadf2e73f00001e", 
      "snippets": [
        {
          "offsetInBeginSection": 498, 
          "offsetInEndSection": 800, 
          "text": "Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody against the IL-6 receptor and has been approved in many countries, including the United States, for the treatment of moderate to severe RA in patients who have not adequately responded to one or more disease-modifying antirheumatic drugs", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24729685", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 714, 
          "offsetInEndSection": 867, 
          "text": "Several clinical studies have demonstrated that a humanized anti-IL-6 receptor antibody, tocilizumab, improves clinical symptoms in rheumatoid arthritis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27790001", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 190, 
          "text": "Tocilizumab is a recombinant humanized antihuman interleukin-6 receptor monoclonal antibody, which inhibits binding of IL-6 to its soluble (sIL-6R) and membrane-expressed (mIL-6R) receptors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22101760", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Where is the protein protamine 2 expressed?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28748416", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28666211", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26801756", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25516990", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24869677"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Human sperm express two types of protamine: protamine 1 (P1) and the family of protamine 2 (P2) proteins."
      ], 
      "exact_answer": [
        [
          "sperm cells"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c9e6407ecadf2e73f000034", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 259, 
          "text": "This work aimed at investigating the effect of resveratrol on (1) DNA integrity and (2) fertilizing capacity of sperm by quantifying the presence of key paternal transcripts considered as markers for male fertility (protamine 1 [PRM1] and protamine 2 [PRM2]) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28748416", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1186, 
          "offsetInEndSection": 1323, 
          "text": "biomarkers associated with spermatogenesis, including azoospermia-like (DAZL), phosphoglycerate kinase 2 (PGK2), and protamine 2 (PRM2). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28666211", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 97, 
          "text": " Protamines are sperm nuclear proteins with a crucial role in chromatin condensation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26801756", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 481, 
          "offsetInEndSection": 570, 
          "text": "Expression of germ cell-specific proteins such as POU5F1, DAZL, TNP1, TNP2, PRM1 and PRM2", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516990", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 105, 
          "text": "Human sperm express two types of protamine: protamine 1 (P1) and the family of protamine 2 (P2) proteins,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24869677", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can miR-122 target RUNX2?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30070328"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes, miR-122 directly targets RUNX2."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5c8fea130101eac87000000d", 
      "snippets": [
        {
          "offsetInBeginSection": 1373, 
          "offsetInEndSection": 1511, 
          "text": "MiR-122 functions as a tumor suppressor by inhibiting proliferation and inducing apoptosis, which is achieved by directly targeting RUNX2.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30070328", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Tocilizumab is an anti-TNF antibody, yes or no?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28401573", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29495891", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19368420", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20979549", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24286116", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26751942", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21949922", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22431927", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24741293", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19882783", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21234291"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Tocilizumab (TCZ) is a humanized monoclonal antibody against IL-6 receptor licensed in 2009 and recommendations consider TCZ as one of the treatements indicated after methotrexate and/or TNF inhibitors failure in adult RA.", 
        "Tocilizumab (TCZ) is a humanized monoclonal antibody against IL-6\u00a0receptor licensed in 2009", 
        "Tocilizumab (TCZ) is a humanized monoclonal antibody against IL-6\u00a0receptor licensed in 2009 that has demonstrated clinical efficacy in various adult RA populations.", 
        "Tocilizumab (TCZ) is a humanized monoclonal antibody against IL-6\u00a0receptor", 
        "was treated with tocilizumab, an anti-interleukin-6 receptor monoclonal antibody"
      ], 
      "exact_answer": "no", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5c960d88ecadf2e73f00001f", 
      "snippets": [
        {
          "offsetInBeginSection": 595, 
          "offsetInEndSection": 676, 
          "text": "was treated with tocilizumab, an anti-interleukin-6 receptor monoclonal antibody ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28401573", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 304, 
          "offsetInEndSection": 658, 
          "text": "Tocilizumab (TCZ) is a humanized monoclonal antibody against IL-6\u00a0receptor licensed in 2009 that has demonstrated clinical efficacy in various adult RA populations. RA management guidelines and recommendations consider TCZ as one of the bDMARDS indicated after methotrexate or other conventional synthetic DMARDs and/or TNF inhibitors failure in adult RA", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29495891", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 137, 
          "text": "Tocilizumab (RoActemra or Actemra) is a recombinant humanized monoclonal antibody that acts as an interleukin (IL)-6 receptor antagonist.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19368420", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 425, 
          "offsetInEndSection": 547, 
          "text": "METHODS\nPatients (n = 93) were treated with an anti-IL-6 receptor antibody (tocilizumab) or TNF-\u03b1 inhibitors for 16 weeks.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24286116", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 340, 
          "text": "The recent development of biological agents, namely, anti-tumour necrosis factor alpha (TNF-\u03b1) agents (infliximab, adalimumab and etanercept), anti- CD20 monoclonal antibody (rituximab) and anti-interleukin 6 receptor (IL-6R) monoclonal antibody (tocilizumab), represents a major breakthrough for the treatment of immune-mediated disorders.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26751942", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 463, 
          "offsetInEndSection": 736, 
          "text": "Recently, an anti-IL-6 receptor monoclonal antibody, tocilizumab, has been licensed for the treatment as monotherapy or in combination with methotrexate of moderate to severe RA, when disease modifying anti-rheumatic drugs or anti-tumour necrosis factors (TNF) have failed.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21949922", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 113, 
          "text": "Tocilizumab is a monoclonal humanized anti-IL-6-receptor antibody used for the treatment of rheumatoid arthritis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22431927", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 377, 
          "offsetInEndSection": 913, 
          "text": "Indeed, worldwide clinical trials of TNF inhibiting biologic disease modifying antirheumatic drugs (bDMARDs) including infliximab, adalimumab, golimumab, certolizumab pegol, and etanercept as well as the humanized anti-human IL-6 receptor antibody, tocilizumab, have demonstrated outstanding clinical efficacy and tolerable safety profiles, resulting in worldwide approval for using these bDMARDs to treat moderate to severe active RA in patients with an inadequate response to synthetic disease modifying antirheumatic drugs (sDMARDs).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24741293", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 209, 
          "text": "Tocilizumab is a humanized anti-IL-6 receptor monoclonal antibody, which binds to circulating soluble IL-6 receptor and membrane-expressed IL-6 receptor, inhibiting IL-6 binding to both forms of IL-6 receptor.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20979549", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 140, 
          "offsetInEndSection": 309, 
          "text": "Subsequent options include a TNF-alpha antagonist, followed by rituximab or possibly abatacept; (2) Tocilizumab, a monoclonal antibody, inhibits interleukin-6 receptors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19882783", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 92, 
          "offsetInEndSection": 177, 
          "text": "Tocilizumab (TCZ) is a monoclonal antibody which inhibits the interleukin-6 receptor.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21234291", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is it possible to analyze exosomes with FACS?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29783743", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30290833", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26598503", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26154623"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes,\na novel strategy for generating metabolically-labeled fluorescent exosomes that can be counted by flow cytometry assay (FACS) and characterized."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5c9e6ab9ecadf2e73f000035", 
      "snippets": [
        {
          "offsetInBeginSection": 1458, 
          "offsetInEndSection": 1516, 
          "text": "whose presence was validated by a bead-exosome FACS assay.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26154623", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 222, 
          "offsetInEndSection": 467, 
          "text": "We analyzed exosomes from mouse (C57Bl/6) and breast, lung, and ovarian cancer patient samples and cultured cancer cells with different approaches, including nanoparticle tracking analysis, biolayer interferometry, FACS, and electron microscopy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598503", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 749, 
          "offsetInEndSection": 924, 
          "text": "we applied a technique to generate native fluorescent exosomes characterized by vesicles integrity, size, density, markers expression, and quantifiable by direct FACS analysis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30290833", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 442, 
          "offsetInEndSection": 594, 
          "text": "we used a novel strategy for generating metabolically-labeled fluorescent exosomes that can be counted by flow cytometry assay (FACS) and characterized.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29783743", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which company developed opdivo?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30293207"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Opdivo or nivolumab was developed by Bristol-Myers Squibb."
      ], 
      "exact_answer": [
        [
          "Bristol-Myers Squibb"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c910ae0ecadf2e73f000007", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 297, 
          "text": "As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Bristol-Myers Squibb) of nivolumab (Opdivo\u00ae) to submit evidence of its clinical and cost effectiveness for metastatic or unresectable urothelial cancer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30293207", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are DMARDs?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27538766", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27604908", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28324149", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23716132", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25630309", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23961667", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28679392", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24129128", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25943001", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23959574", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24470443", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12468815", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7732491", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25943002", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22420649", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25244345", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22298075", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25504789", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20681888", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9608316", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30448932", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25603037", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18824833"
      ], 
      "triples": [], 
      "ideal_answer": [
        "DMARDs are Disease Modifying anti-rheumatic drugs (DMARD).", 
        "Treatment with disease-modifying antirheumatic drugs (DMARDs) was 61% (claims data)", 
        "Treatment with disease-modifying antirheumatic drugs (DMARDs) was 61% (claims data) and", 
        "Treatment with disease-modifying antirheumatic drugs (DMARDs)", 
        "To determine the utility of ultrasonography in guiding modification of disease-modifying anti-rheumatic drug (DMARD) and steroid therapy for inflammatory arthritis (IA)"
      ], 
      "exact_answer": [
        [
          "Disease Modifying anti-rheumatic drugs"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c960f21ecadf2e73f000020", 
      "snippets": [
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 179, 
          "text": "To determine the utility of ultrasonography in guiding modification of disease-modifying anti-rheumatic drug (DMARD) and steroid therapy for inflammatory arthritis (IA)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27538766", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 216, 
          "offsetInEndSection": 262, 
          "text": "disease-modifying antirheumatic drugs (DMARDs)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27604908", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1290, 
          "offsetInEndSection": 1352, 
          "text": "Treatment with disease-modifying antirheumatic drugs (DMARDs) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28324149", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 49, 
          "text": "[DMARDs (disease-modifying antirheumatic drugs)].", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23961667", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 145, 
          "text": "Disease-modifying antirheumatic drugs (DMARDs) have largely contributed to recent paradigm shift of rheumatoid arthritis (RA) treatment strategy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23961667", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 129, 
          "text": "BACKGROUND\nBiologic disease-modifying antirheumatic drugs (DMARDs) are increasingly used for rheumatoid arthritis (RA) treatment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28679392", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 224, 
          "text": "Tocilizumab (TCZ) and tumour necrosis factor inhibitors (TNFi) are recommended for the treatment of rheumatoid arthritis (RA) in patients with inadequate response (IR) to prior disease-modifying antirheumatic drugs (DMARDs).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25630309", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 308, 
          "text": "BACKGROUND\nRheumatoid arthritis (RA) is a progressive autoimmune disorder of joints that is associated with high health care costs, yet guidance is lacking on how early to initiate biologic disease-modifying antirheumatic drugs (DMARDs), a class of medications that is the major cost driver in RA management.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25943001", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 148, 
          "text": "BACKGROUND\nTherapy of rheumatoid arthritis (RA) is typically characterized by the sequential use of disease-modifying anti-rheumatic drugs (DMARDs).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12468815", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 222, 
          "text": "There are only six DMARDs (disease modifying anti-rheumatic drugs) available in the clinical practice, such as gold sodium thiomalate, D-penicillamine, bucillamine, auranofin, salazosulphapyridine, and lobenzarit disodium.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7732491", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 152, 
          "text": "Tofacitinib (Xeljanz(\u00ae)) is the first approved drug in a new class of disease modifying antirheumatic drugs (DMARDs), the Janus kinase (JAK) inhibitors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23716132", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 180, 
          "text": "OBJECTIVE\nDisease-modifying antirheumatic drugs (DMARDs) are the standard of care for rheumatoid arthritis (RA); however, studies have found that many patients do not receive them.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24470443", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 165, 
          "text": "Disease-modifying anti-rheumatic drugs (DMARDs) are the cornerstone of rheumatoid arthritis (RA) pharmacotherapy and should be initiated promptly after RA diagnosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23959574", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 184, 
          "text": "OBJECTIVES\nWhen rheumatoid arthritis (RA) patients have achieved sustained good clinical responses can their disease-modifying anti-rheumatic drugs (DMARDs) be reduced or discontinued?", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24129128", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 302, 
          "text": "BACKGROUND\nGiven the availability of a number of alternative biologic treatment options and other novel disease-modifying antirheumatic drugs (DMARDs) for the treatment of patients with rheumatoid arthritis (RA), clinicians are faced with an increasingly challenging choice regarding optimal treatment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25943002", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 245, 
          "text": "BACKGROUND\nTreatment of juvenile idiopathic arthritis (JIA) with disease-modifying antirheumatic drugs (DMARDs) may improve outcomes compared to conventional therapy (e.g., non-steroidal anti-inflammatory drugs, intra-articular corticosteroids).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22420649", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 195, 
          "text": "Disease modifying antirheumatic drugs (DMARDs) is a category of drugs which is used as medication in various arthritic conditions to arrest the progression of disease along with relief from pain.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25244345", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 156, 
          "offsetInEndSection": 330, 
          "text": "For this purpose, all patients with the diagnosis of RA should be treated by disease-modifying antirheumatic drugs (DMARDs) including biologic DMARDs and non-biologic DMARDs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22298075", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 327, 
          "offsetInEndSection": 408, 
          "text": "(2) What is the search volume for disease-modifying antirheumatic drugs (DMARDs)?", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30448932", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 234, 
          "text": "<b>OBJECTIVES</b>: Patients and rheumatologists have a number of options to consider for the treatment of rheumatoid arthritis (RA), including biologic response modifier (BRM) therapy and diseasemodifying antirheumatic drugs (DMARDs).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18824833", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 193, 
          "text": "To explore what considerations patients have when deciding about disease-modifying antirheumatic drugs (DMARDs) and what information patients need to participate in the decision-making process.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25504789", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 186, 
          "text": "Disease-modifying antirheumatic drug (DMARD) therapy is now clearly accepted as the primary treatment for rheumatoid arthritis, with an increasing emphasis on use of combination therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9608316", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 304, 
          "offsetInEndSection": 385, 
          "text": "(2) What is the search volume for disease-modifying antirheumatic drugs (DMARDs)?", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30448932", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 160, 
          "text": "The efficacy of the biologic disease-modifying antirheumatic drugs (DMARDs) shown in clinical trials may be jeopardized due to prevalent poor patient adherence.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20681888", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 169, 
          "offsetInEndSection": 496, 
          "text": "Although methotrexate has retained its place as the first-line agent, there has been great interest in comparing biologicals to conventional Disease Modifying Anti Rheumatic Drugs (DMARDs) over the past few years with the updated guidelines from both the American College of Rheumatology and European League Against Rheumatism.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25603037", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the aim of the MitoCeption protocol?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28287607", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25766410"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The MitoCeption protocol directly and quantitatively transfer mitochondria, isolated from cell type A, to recipient cell type B."
      ], 
      "exact_answer": [
        [
          "Mitochondrial transfer"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c9e6e99ecadf2e73f000036", 
      "snippets": [
        {
          "offsetInBeginSection": 782, 
          "offsetInEndSection": 1000, 
          "text": " The MitoCeption protocol described here allows the transfer of the mitochondria isolated beforehand from the donor cells to the target cells, using MSC mitochondria and glioblastoma stem cells (GSC) as a model system.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28287607", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 474, 
          "offsetInEndSection": 618, 
          "text": "We designed a protocol (MitoCeption) to directly and quantitatively transfer mitochondria, isolated from cell type A, to recipient cell type B. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25766410", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can prevnar 13 be used in children?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22045904"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes, PCV13 is approved for routine vaccination of all infants as a 4-dose series at age 2, 4, 6, and 12-15 months for children who previously received 1 or more doses of the 7-valent pneumococcal conjugate vaccine (PCV7), and for children with underlying medical conditions that increase their risk for pneumococcal disease or its complications."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5c915e51ecadf2e73f00000c", 
      "snippets": [
        {
          "offsetInBeginSection": 721, 
          "offsetInEndSection": 1062, 
          "text": "PCV13 is approved for routine vaccination of all infants as a 4-dose series at age 2, 4, 6, and 12-15 months for children who previously received 1 or more doses of the 7-valent pneumococcal conjugate vaccine (PCV7), and for children with underlying medical conditions that increase their risk for pneumococcal disease or its complications. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22045904", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1299, 
          "offsetInEndSection": 1580, 
          "text": "Based on published immunogenicity and safety data, as well as the recent recommendations by the ACIP for routine use in infants and indications for high-risk pediatric patients, PCV13 is a revised formulation of pneumococcal vaccine that should be included on pharmacy formularies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22045904", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 148, 
          "text": "To review the immunogenicity, efficacy, and safety of the 13-valent pneumococcal conjugate vaccine (PCV13) for use in pediatric patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22045904", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Was stelara developed by Amgen?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28976302"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Stelara was developed by Janssen Pharmaceuticals, Inc., Horsham, PA, USA."
      ], 
      "exact_answer": "no", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5c9160bcecadf2e73f00000d", 
      "snippets": [
        {
          "offsetInBeginSection": 264, 
          "offsetInEndSection": 484, 
          "text": "NICE does not specifically recommend switching from one biologic to another, and only ustekinumab (UST; STELARA\u00ae, Janssen Pharmaceuticals, Inc., Horsham, PA, USA) is recommended after anti-tumour necrosis factor failure.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28976302", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List off label uses for Rituximab.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28536935", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29797711", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28742259", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29574922", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30185361", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18270863"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Off label uses for rituximab are for poly- and dermatomyositis, multiple sclerosis, immune thrombocytopenia, systemic lupus erythematosus (SLE), lupus nephritis (LN), and other immune diseases."
      ], 
      "exact_answer": [
        [
          "poly- and dermatomyositis"
        ], 
        [
          "multiple sclerosis"
        ], 
        [
          "auto immune disease"
        ], 
        [
          "immune thrombocytopenia"
        ], 
        [
          "systemic lupus erythematosus (SLE)"
        ], 
        [
          "lupus nephritis (LN)"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "5c961603ecadf2e73f000022", 
      "snippets": [
        {
          "offsetInBeginSection": 265, 
          "offsetInEndSection": 491, 
          "text": "Analysis of the data of the GRAID-2 registry for poly- and dermatomyositis.RESULTS: In 22\u00a0of the 23\u00a0patients in the GRAID-2 registry, rituximab (RIX) was administered, while 1\u00a0patient was given tocilizumab as off-label therapy", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28536935", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 77, 
          "text": "Off-label use of rituximab to treat MS patients in Sweden is high", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29797711", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 101, 
          "text": "Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008-2016.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28742259", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 17, 
          "offsetInEndSection": 376, 
          "text": "immune thrombocytopenia who do not adequately respond to first-line therapy, there is no clear consensus on which second-line therapy to initiate and when. This situation leads to suboptimal approaches, including prolonged exposure to treatments that are not intended for long-term use (eg, corticosteroids) and overuse of off-label therapies (eg, rituximab) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29574922", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 288, 
          "text": "Conventional treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN) is associated with damage accrual, hence increased morbidity rate. Off-label use of rituximab (RTX) has shown significant promise in this patient group; however, data are still controversial.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30185361", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 67, 
          "text": "Outcomes of rituximab therapy in refractory lupus: A meta-analysis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30185361", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 811, 
          "offsetInEndSection": 1077, 
          "text": "Rituximab seems to have an interesting benefit-to-risk ratio in Wegener granulomatosis (excepted in granulomatous lesions), HCV-associated symptomatic cryoglobulinemia in patients unresponsive to anti-viral therapy, pemphigus and thrombotic thrombocytopenic purpura.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18270863", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can mitochondria pass through membrane nanotubes?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29335691", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29362447"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes,\nMembrane nanotubes (MNTs) act as \"highways\" between cells to facilitate the transfer of multiple signals and play an important role in many diseases. Our previous work reported on the transfer of mitochondria via MNTs between cardiomyocytes (CMs) and cardiac myofibroblasts (MFs)."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5c9e766becadf2e73f000038", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 279, 
          "text": "Membrane nanotubes (MNTs) act as \"highways\" between cells to facilitate the transfer of multiple signals and play an important role in many diseases. Our previous work reported on the transfer of mitochondria via MNTs between cardiomyocytes (CMs) and cardiac myofibroblasts (MFs)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29362447", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 124, 
          "text": "Membrane nanotubes play important functional roles in numerous cell activities such as cellular transport and communication.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29335691", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is Quorum Sensing in bacteria?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29130162", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29130160", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29095463", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27688408", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15151251", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22825856", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23125205", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27634359", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22269240", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20819164"
      ], 
      "triples": [], 
      "ideal_answer": [
        "In most bacteria, a global level of regulation, termed quorum sensing (QS), exists involving intercellular communication via the production and response to cell density-dependent signal molecules.", 
        "In many pathogenic microorganisms, communication systems, collectively termed quorum sensing (QS), have been observed", 
        "In many pathogenic microorganisms, communication systems, collectively termed quorum sensing (QS),"
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "5c978924ecadf2e73f000023", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 174, 
          "text": "Many Proteobacteria synthesize acyl-homoserine lactone (AHL) molecules for use as signals in cell density-dependent gene regulation known as quorum sensing (QS) and response.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29130162", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 197, 
          "text": "In most bacteria, a global level of regulation, termed quorum sensing (QS), exists involving intercellular communication via the production and response to cell density-dependent signal molecules. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29130160", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 358, 
          "offsetInEndSection": 596, 
          "text": " In many pathogenic microorganisms, communication systems, collectively termed quorum sensing (QS), have been observed to control a number of bacterial behaviours including expression of virulence factors and the development of biofilms. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29095463", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 825, 
          "offsetInEndSection": 1049, 
          "text": "Bacteria can communicate within their own species (intra-species) but also between species (inter-species), for which they employ an autoinducer-2 quorum sensing system which is called the universal language of the bacteria.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27688408", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 217, 
          "text": "Quorum sensing is a signaling mechanism through which bacteria modulate a number of cellular functions (genes), including sporulation, biofilm formation, bacteriocin production, virulence responses, as well as others.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15151251", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 218, 
          "offsetInEndSection": 395, 
          "text": "Quorum sensing is a mechanism of cell-to-cell communication and is mediated by extracellular chemical signals generated by the bacteria when specific cell densities are reached.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15151251", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 117, 
          "text": "Quorum sensing is used by a large variety of bacteria to regulate gene expression in a cell-density-dependent manner.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22825856", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "BACKGROUND\nQuorum sensing or the bacterial information flow in an orchestrated manner is an essential feature of many pathogenic bacteria.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27634359", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 931, 
          "offsetInEndSection": 1056, 
          "text": "Quorum sensing is the means of communication between these bacteria to regulate a wide range of behavior patterns among them.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22269240", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 155, 
          "text": "Quorum sensing is a process of cell-cell communication that allows bacteria to share information about cell density and adjust gene expression accordingly.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23125205", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 103, 
          "text": "Quorum sensing is the phenomenon, whereby bacteria use signal molecules to communicate with each other.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20819164", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 153, 
          "text": "The term 'quorum sensing' describes intercellular bacterial communication which regulates bacterial gene expression according to population cell density.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27688408", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the cause of Krabbe disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28598007", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29316812", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29391017"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Globoid cell leukodystrophy (GLD), or Krabbe disease, is an inherited, neurologic disorder that results from deficiency of a lysosomal enzyme, galactosylceramidase."
      ], 
      "exact_answer": [
        [
          "deficiency of \u03b2-galactocerebrosidase"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c9efde8ecadf2e73f000039", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 90, 
          "text": "Krabbe disease (KD) is a rare disease caused by the deficiency of \u03b2-galactocerebrosidase. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28598007", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 164, 
          "text": "Globoid cell leukodystrophy (GLD), or Krabbe disease, is an inherited, neurologic disorder that results from deficiency of a lysosomal enzyme, galactosylceramidase.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29316812", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 118, 
          "text": "Krabbe disease is a rare neurodegenerative genetic disorder caused by deficiency of galactocerebrosidase. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29391017", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Name a CFL2 mutation which is associated with nemaline myopathy?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22560515"
      ], 
      "triples": [], 
      "ideal_answer": [
        "A mutation in CFL2 was identified in a family with nemaline myopathy, namely a homozygous missense mutation in exon 2 (c.19G>A, p.Val7Met)."
      ], 
      "exact_answer": [
        [
          "c.19G>A", 
          "p.Val7Met"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c89623bf9c2ba6b28000004", 
      "snippets": [
        {
          "offsetInBeginSection": 469, 
          "offsetInEndSection": 703, 
          "text": "Because a mutation in CFL2 was identified in a family with nemaline myopathy, we performed sequence analysis of the gene and a novel homozygous missense mutation in exon 2 (c.19G>A, p.Val7Met) of CFL2 was identified in both siblings. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560515", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What cellular process is the gene product of NANOG involved in?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28866747", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29177763", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29243835", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29204746", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29414604", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29486740", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26339994"
      ], 
      "triples": [], 
      "ideal_answer": [
        "NANOG is a transcription factor and a biomarker of cancer and pluripotent stem cells."
      ], 
      "exact_answer": [
        [
          "regulation of transcription"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c9789a9ecadf2e73f000024", 
      "snippets": [
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 187, 
          "text": "The objective of this study was to explore the prognostic value of cancer stem cell markers, namely CD133, NANOG, and NOTCH1, in early stage oral squamous cell carcinoma (OSCC)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28866747", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 320, 
          "offsetInEndSection": 378, 
          "text": " transcription factors (TFs) such as Oct4, Sox2, and Nanog", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29177763", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 569, 
          "offsetInEndSection": 636, 
          "text": "expression of breast CSCs markers (CD44, ALDH1A1, Nanog, and Oct4),", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29243835", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1266, 
          "offsetInEndSection": 1310, 
          "text": "pluripotency markers OCT-4, SOX-2 and NANOG ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29204746", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 232, 
          "offsetInEndSection": 377, 
          "text": "The obtained induced pluripotent stem cell (iPSC) line showed pluripotency verified by the expression of pluripotency markers, NANOG, SOX2, OCT4,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29414604", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 128, 
          "offsetInEndSection": 226, 
          "text": "Nanog is one of the transcription factors that are essential for stem cellular physiology process.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26339994", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 975, 
          "offsetInEndSection": 1069, 
          "text": "CONCLUSIONS\nNanog has been recognized as a critical pluripotency gene in stem cell regulation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29486740", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Name the uses of Sideritis scardica in traditional medicine.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24487281"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Sideritis scardica is used in traditional medicine as a loosening agent in bronchitis and bronchial asthma; against the common cold and lung emphysema; in the treatment of inflammation, gastrointestinal disorders and coughs; and as an active constituent of dietary supplements for the prevention of anemia. Sideritis scardica has been attributed a broad range of properties such as antimicrobial, anti-inflammatory, cytotoxic, antioxidant, gastroprotective, antiglioma, and triple monoamine reuptake inhibition."
      ], 
      "exact_answer": [
        [
          "against inflammation"
        ], 
        [
          "against gastrointestinal disorders"
        ], 
        [
          "against anemia"
        ], 
        [
          "against bronchitis"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "5c890ff475a4a5d219000010", 
      "snippets": [
        {
          "offsetInBeginSection": 106, 
          "offsetInEndSection": 396, 
          "text": "It is used in traditional medicine as a loosening agent in bronchitis and bronchial asthma; against the common cold and lung emphysema; in the treatment of inflammation, gastrointestinal disorders and coughs; and as an active constituent of dietary supplements for the prevention of anemia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24487281", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1413, 
          "offsetInEndSection": 1777, 
          "text": "A broad range of activities of plant extracts and fractions as antimicrobial, anti-inflammatory, cytotoxic, antioxidant, gastroprotective, antiglioma, and triple monoamine reuptake inhibition as well as cultivation of the species as an approach for conservation of the natural habitats and provision of herb with high and permanent quality has also been presented.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24487281", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are the phenotypic features of the autosomal dominant, development disease, Noonans syndrome", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28144274", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29084544", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24447602", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20882035", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12439898"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Noonan syndrome is an autosomal dominant disease and is characterized by developmental problems. Symptoms have been reported for this abnormality such as short stature, unusual facial characteristics, congenital heart abnormalities, developmental complications, and an elevated tumor incidence rate", 
        "Noonan syndrome (NS) is an autosomal dominant disorder with vast heterogeneity in clinical and genetic features. Various symptoms have been reported for this abnormality such as short stature, unusual facial characteristics, congenital heart abnormalities, developmental complications, and an elevated tumor incidence rate"
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "5c978a2aecadf2e73f000025", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 322, 
          "text": "Noonan syndrome (NS) is an autosomal dominant disorder with vast heterogeneity in clinical and genetic features. Various symptoms have been reported for this abnormality such as short stature, unusual facial characteristics, congenital heart abnormalities, developmental complications, and an elevated tumor incidence rate", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28144274", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 605, 
          "text": "Noonan syndrome (NS) and Noonan syndrome with multiple lentigines (NSML) are autosomal dominant developmental disorders. NS and NSML are caused by abnormalities in genes that encode proteins related to the RAS-MAPK pathway, including PTPN11, RAF1, BRAF, and MAP2K. In this study, we diagnosed ten NS or NSML patients via targeted sequencing or whole exome sequencing (TS/WES).METHODS: TS/WES was performed to identify mutations in ten Chinese patients who exhibited the following manifestations: potential facial dysmorphisms, short stature, congenital heart defects, and developmental delay. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29084544", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 181, 
          "text": "Noonan's syndrome is an autosomal dominant genetic disorder with high phenotypic variability, characterized mainly by facial dysmorphism, congenital heart disease and short stature.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24447602", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 152, 
          "text": "Noonan syndrome is an autosomal dominant disease characterized by dysmorphic features, webbed neck, cardiac anomalies, short stature and cryptorchidism.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20882035", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 132, 
          "text": "Noonan syndrome or new autosomal dominant condition with coarctation of the aorta, hypertrophic cardiomyopathy, and minor anomalies.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12439898", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 269, 
          "text": "This is a report on a father and his two children with an apparent autosomal dominant condition characterized by craniofacial anomalies, coarctation of the aorta, hypertrophic cardiomyopathy, and other structural heart abnormalities with normal psychomotor development.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12439898", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are protamines ubiquitously expressed?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29797354"
      ], 
      "triples": [], 
      "ideal_answer": [
        "No,\nProtamines are nuclear proteins which are specifically expressed in haploid male germ cells."
      ], 
      "exact_answer": "no", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5c9f1b0cecadf2e73f00003c", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 92, 
          "text": "Protamines are nuclear proteins which are specifically expressed in haploid male germ cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29797354", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are Crocus sativus compounds being considered against Alzheimer's disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28471166"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes, it has been observed that Crocus sativus extracts and compounds have a positive effect against Alzheimer's disease."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5c891d5075a4a5d219000011", 
      "snippets": [
        {
          "offsetInBeginSection": 169, 
          "offsetInEndSection": 439, 
          "text": "Previous evidence suggested that Crocus sativus is linked to improving cognitive function in Alzheimer's disease (AD) patients. The aim of this study was to in vitro and in vivo investigate the mechanism(s) by which Crocus sativus exerts its positive effect against AD. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28471166", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1551, 
          "offsetInEndSection": 1690, 
          "text": "Collectively, findings from this study support the positive effect of Crocus sativus against AD by reducing A\u03b2 pathological manifestations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28471166", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Rickettsia felis was described as a human pathogen almost two decades ago, what is it's main arthropod vector?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29079185", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29217417", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24149035", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21722253", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19645274", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26824189"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Cat fleas (Ctenocephalides felis) carry Rickettsia felis", 
        "Cat fleas (Ctenocephalides felis) carrying Rickettsia felis and Bartonella species in Hong Kong.", 
        "Cat fleas (Ctenocephalides felis) carrying Rickettsia felis and Bartonella species in Hong Kong"
      ], 
      "exact_answer": [
        [
          "Cat fleas (Ctenocephalides felis)"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c9791d2ecadf2e73f000026", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "Cat fleas (Ctenocephalides felis) carrying Rickettsia felis and Bartonella species in Hong Kong.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29217417", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 231, 
          "offsetInEndSection": 358, 
          "text": " Morphological examination of 174 fleas from dogs and cats living in Hong Kong revealed only cat fleas (Ctenocephalides felis).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29217417", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 375, 
          "offsetInEndSection": 560, 
          "text": "The main arthropod reservoir and vector is the cat flea, Ctenocephalides felis, yet more than 20 other species of fleas, ticks, and mites species have been reported to harbour R. felis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24149035", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 207, 
          "offsetInEndSection": 437, 
          "text": "The cat flea, Ctenocephalides felis, is currently the only known biological vector of R. felis; however, molecular evidence of R. felis in other species of fleas as well as in ticks and mites suggests a variety of arthropod hosts.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19645274", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 451, 
          "text": "Rickettsia felis: from a rare disease in the USA to a common cause of fever in sub-Saharan Africa.Rickettsia felis is a spotted fever group rickettsia that has been definitely described in 2002. Within the last 20 years, there have been a growing number of reports implicating R. felis as a human pathogen, parallel to the fast-growing reports of the worldwide detection of R. felis in arthropod hosts, mainly the cat flea Ctenocephalides felis felis. ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21722253", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 437, 
          "offsetInEndSection": 622, 
          "text": "The main arthropod reservoir and vector is the cat flea, Ctenocephalides felis, yet more than 20 other species of fleas, ticks, and mites species have been reported to harbour R. felis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24149035", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 98, 
          "offsetInEndSection": 234, 
          "text": "Another rickettsia, Rickettsia felis, found in cat fleas, Ctenocephalides felis, has also been implicated as a potential human pathogen.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26824189", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are there any anti-amyloid antibody approved as drug for Alzheimer's disease treatment?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26697860", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29607687"
      ], 
      "triples": [], 
      "ideal_answer": [
        "No new drugs have been approved during the past 15 years; and the available medications are not cost-effective."
      ], 
      "exact_answer": "no", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5ca0848aecadf2e73f000044", 
      "snippets": [
        {
          "offsetInBeginSection": 873, 
          "offsetInEndSection": 1222, 
          "text": "Treatment with memantine, a noncompetitive NMDA receptor antagonist which is an approved drug for treatment of Alzheimer's disease, rescued protein phosphatase-2A activity by decreasing its demethylation at Leu309 selectively and attenuated Alzheimer's disease-like pathology and cognitive impairment in adeno-associated virus vector-1-I1PP2A rats. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26697860", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 598, 
          "offsetInEndSection": 626, 
          "text": "anti-Amyloid agents (13.30%)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29607687", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 202, 
          "offsetInEndSection": 314, 
          "text": "no new drugs have been approved during the past 15\u00a0years; and the available medications are not cost-effective. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29607687", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Do Crocus sativus extracts loosen the blood-brain barrier?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28471166"
      ], 
      "triples": [], 
      "ideal_answer": [
        "No, in vitro and in vivo experiments show that the Crocus sativus extract increases the tightness of a cell-based blood-brain barrier (BBB)."
      ], 
      "exact_answer": "no", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5c891e5575a4a5d219000012", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "Crocus sativus Extract Tightens the Blood-Brain Barrier, Reduces Amyloid \u03b2 Load and Related Toxicity in 5XFAD Mice.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28471166", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 523, 
          "offsetInEndSection": 1120, 
          "text": "In vitro results showed that Crocus sativus extract increases the tightness of a cell-based blood-brain barrier (BBB) model and enhances transport of A\u03b2. Further in vivo studies confirmed the effect of Crocus sativus extract (50 mg/kg/day, added to mice diet) on the BBB tightness and function that was associated with reduced A\u03b2 load and related pathological changes in 5XFAD mice used as an AD model. Reduced A\u03b2 load could be explained, at least in part, by Crocus sativus extract effect to enhance A\u03b2 clearance pathways including BBB clearance, enzymatic degradation and ApoE clearance pathway.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28471166", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are artificial blood cells available?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20234994", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28406466"
      ], 
      "triples": [], 
      "ideal_answer": [
        "No,\nThe critical point for the break through for artificial blood products did not come yet but could be ahead-"
      ], 
      "exact_answer": "no", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5ca0fa96ecadf2e73f000048", 
      "snippets": [
        {
          "offsetInBeginSection": 1638, 
          "offsetInEndSection": 1745, 
          "text": "The critical point for the break through for artificial blood products did not come yet but could be ahead-", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20234994", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 280, 
          "text": "We suggest a novel method that uses artificial blood cells (hemoglobin vesicles, Hb-Vs) as photosensitizers in dye laser treatment (at 595-nm wavelength) for port-wine stains (i.e., capillary malformations presenting as red birthmarks) based on the results of animal experiments. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28406466", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Have apolipoprotein mimetics been used in clinical trials?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25157031"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes, apolipoprotein mimetics have entered clinical trials."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5c895cf0f9c2ba6b28000001", 
      "snippets": [
        {
          "offsetInBeginSection": 1230, 
          "offsetInEndSection": 1329, 
          "text": "One of these (AEM-28) has recently been given orphan drug status and is undergoing clinical trials.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25157031", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are 2 organisms that can cause Human toxocariasis?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29733009", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24808249", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28761463", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18179629", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25910623", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30050644"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Human toxocariasis, a worldwide parasitic disease, is caused by the larval stage of intestinal nematodes of dogs and cats, namely Toxocara canis and Toxocara cati", 
        "human toxocariasis, a worldwide parasitic disease, is caused by the larval stage of intestinal nematodes of dogs and cats, namely toxocara canis and toxocara cati", 
        "Human toxocariasis , a worldwide parasitic disease , is caused by the larval stage of intestinal nematodes of dogs and cats , namely Toxocara canis and Toxocara cati"
      ], 
      "exact_answer": [
        [
          "Toxocara cati"
        ], 
        [
          "Toxocara canis"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "5c979ffcecadf2e73f000028", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 162, 
          "text": "Human toxocariasis, a worldwide parasitic disease, is caused by the larval stage of intestinal nematodes of dogs and cats, namely Toxocara canis and Toxocara cati", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29733009", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 175, 
          "text": "Human toxocariasis which is caused mainly by the larvae of Toxocara canis and Toxocara cati, is a worldwide zoonotic disease that can be a potentially serious human infection.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25910623", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 186, 
          "text": "BACKGROUND\nToxocariasis is a prevalent zoonosis disease caused by the closely related nematode species Toxocara canis and Toxocara cati which parasitise Canidae and Felidae respectively.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28761463", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 134, 
          "text": "Human toxocariasis is a zoonosis caused by infection with larvae of the ascarid nematode Toxocara canis and, less frequently, T. cati.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18179629", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 133, 
          "text": "Toxocariasis is a preventable parasitic disease that is caused by the dog and cat roundworms Toxocara cani and T. cati, respectively.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24808249", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 137, 
          "text": "Human toxocariasis is a cosmopolitan parasitic zoonosis caused by Toxocara canis and Toxocara cati which are roundworms of dogs and cats.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30050644", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the dbSUPER database?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26438538"
      ], 
      "triples": [], 
      "ideal_answer": [
        "dbSUPER is the first integrated and interactive database of super-enhancers, with the primary goal of providing a resource for assistance in further studies related to transcriptional control of cell identity and disease. dbSUPER provides a responsive and user-friendly web interface to facilitate efficient and comprehensive search and browsing. The data can be easily sent to Galaxy instances, GREAT and Cistrome web-servers for downstream analysis, and can also be visualized in the UCSC genome browser where custom tracks can be added automatically. The data can be downloaded and exported in variety of formats. Furthermore, dbSUPER lists genes associated with super-enhancers and also links to external databases such as GeneCards, UniProt and Entrez. dbSUPER also provides an overlap analysis tool to annotate user-defined regions."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "5c8960a6f9c2ba6b28000003", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 65, 
          "text": "dbSUPER: a database of super-enhancers in mouse and human genome.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26438538", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 565, 
          "offsetInEndSection": 1460, 
          "text": "We developed dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/), the first integrated and interactive database of super-enhancers, with the primary goal of providing a resource for assistance in further studies related to transcriptional control of cell identity and disease. dbSUPER provides a responsive and user-friendly web interface to facilitate efficient and comprehensive search and browsing. The data can be easily sent to Galaxy instances, GREAT and Cistrome web-servers for downstream analysis, and can also be visualized in the UCSC genome browser where custom tracks can be added automatically. The data can be downloaded and exported in variety of formats. Furthermore, dbSUPER lists genes associated with super-enhancers and also links to external databases such as GeneCards, UniProt and Entrez. dbSUPER also provides an overlap analysis tool to annotate user-defined regions. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26438538", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List places in the body where somatostatin is produced.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25777539", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24627166", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23894587", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23370538", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19819962"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Somatostatin is a cyclic peptide well known for its strong regulatory effects throughout the body. Also known by the name of growth hormone inhibiting hormone, it is produced in many locations, which include the olfactory bulb, hair follicles, pancreas, retina, and central nervous system (CNS)."
      ], 
      "exact_answer": [
        [
          "Hair follicles"
        ], 
        [
          "CNS"
        ], 
        [
          "pancreas"
        ], 
        [
          "olfactory bulb"
        ], 
        [
          "retina"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "5c97f579ecadf2e73f00002a", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 100, 
          "text": "Somatostatin (SST) is a neuromodulator which is abundant throughout the central nervous system (CNS)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25777539", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 123, 
          "text": "Somatostatin (SST) is abundantly produced by the human retina, and the main source is the retinal pigment epithelium (RPE).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24627166", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 123, 
          "text": "Somatostatin (Som), one of the most concentrated neuropeptides in the brain, is highly expressed in the olfactory bulb (OB)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23894587", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 110, 
          "text": "The production of somatostatin interneurons in the olfactory bulb is regulated by the transcription factor sp8", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23894587", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 90, 
          "text": "Somatostatin expression in human hair follicles and its potential role in immune privilege", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23370538", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 98, 
          "text": "The kinetics of insulin, glucagon and somatostatin release was studied in human pancreatic islets.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19819962", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 126, 
          "text": "Glucose generates coincident insulin and somatostatin pulses and antisynchronous glucagon pulses from human pancreatic islets.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19819962", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Is the Philadelphia chromosome a fusion between parts of chromosomes 1 and 9?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29046997", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29435292", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29633730"
      ], 
      "triples": [], 
      "ideal_answer": [
        "No,\nChronic myeloid leukemia is a stem cell disease with the presence of Philadelphia chromosome generated through reciprocal translocation of chromosome 9 and 22."
      ], 
      "exact_answer": "no", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5ca10fefecadf2e73f00004a", 
      "snippets": [
        {
          "offsetInBeginSection": 192, 
          "offsetInEndSection": 388, 
          "text": " The Philadelphia chromosome, t(9;22)(q34;q11), is present in 95% of CML patients, resulting in constitutive tyrosine kinase activity; however, ~5% of CML patients possess a Philadelphia variant. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29435292", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 181, 
          "text": "Chronic Myeloid Leukemia (CML) is myeloproliferative neoplasm characterized by Philadelphia chromosome which is a balanced translocation between chromosome 9 and 22 in 90% of cases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29633730", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 160, 
          "text": "Chronic myeloid leukemia is a stem cell disease with the presence of Philadelphia chromosome generated through reciprocal translocation of chromosome 9 and 22. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29046997", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is YESCARTA?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29501911"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yescarta is an autologous chimeric antigen receptor (CAR) T cell therapy approved by the FDA. Yescarta\u2122 is approved for the treatment of adult patients with R/R large B cell lymphoma. It is a CD19-specific CAR T cell therapy lysing CD19-positive targets."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "5c896ce0d558e5f232000002", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 442, 
          "text": "Two autologous chimeric antigen receptor (CAR) T cell therapies (Kymriah\u2122 and Yescarta\u2122) were recently approved by the FDA. Kymriah\u2122 is for the treatment of pediatric patients and young adults with refractory or relapse (R/R) B cell precursor acute lymphoblastic leukemia and Yescarta\u2122 is for the treatment of adult patients with R/R large B cell lymphoma. In common, both are CD19-specific CAR T cell therapies lysing CD19-positive targets. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29501911", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are the 3 types of immunoglobulin heavy chain containing antibodies found in human breast milk?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28586632"
      ], 
      "triples": [], 
      "ideal_answer": [
        "IgA, IgG, AND  IgM can be found in human milk."
      ], 
      "exact_answer": [
        [
          "IgM"
        ], 
        [
          "IgA"
        ], 
        [
          "IgG"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "5c9f79c3ecadf2e73f00003d", 
      "snippets": [
        {
          "offsetInBeginSection": 590, 
          "offsetInEndSection": 887, 
          "text": "This is a descriptive cross-sectional study of a convenience sample of 67 donated colostrum samples at different days after delivery, both raw and pasteurized. Antibody profiles were analyzed at different times during breastfeeding, and total and specific antibodies (IgM, IgA, and IgG subclasses)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28586632", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is a exposome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28836271", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28494612", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29169635", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29676625"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The exposome is a novel conceptual framework that allows for concurrent examination of multiple intrinsic and extrinsic factors, including environmental exposures, as well as changes in exposures over time, to elucidate the complex environmental factors that affect health outcomes."
      ], 
      "exact_answer": [
        [
          "environmental exposure record"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5cb0d647ecadf2e73f000059", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 205, 
          "text": "The interaction between the (epi)genetic makeup of an individual and his/her environmental exposure record (exposome) is accepted as a determinant factor for a significant proportion of human malignancies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28836271", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 897, 
          "offsetInEndSection": 1109, 
          "text": "The high-throughput and holistic approaches to biomarker discovery used extensively in large-scale molecular epidemiological exposome are also discussed in the context of human exposure to environmental stressors", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28494612", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 499, 
          "offsetInEndSection": 679, 
          "text": "Experimental data strongly suggests a complex interaction between the exposome (or environmental influences) and genome (genetic material) to produce epigenetic changes (epigenome)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29169635", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1095, 
          "offsetInEndSection": 1307, 
          "text": "Exposome factors including nutrition, medication, occupational factors, pollutants, climatic factors, and psychosocial and lifestyle factors may impact on the course and severity of acne and on treatment efficacy", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29377341", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 425, 
          "offsetInEndSection": 708, 
          "text": " The exposome is a novel conceptual framework that allows for concurrent examination of multiple intrinsic and extrinsic factors, including environmental exposures, as well as changes in exposures over time, to elucidate the complex environmental factors that affect health outcomes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29676625", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What does the strimvelis treatment consist of?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29625577"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Strimvelis consists of autologous CD34+ cells transduced to express adenosine deaminase [ADA]."
      ], 
      "exact_answer": [
        [
          "autologous CD34+ cells transduced to express adenosine deaminase"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c897167d558e5f232000005", 
      "snippets": [
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 342, 
          "text": "Strimvelis (autologous CD34+ cells transduced to express adenosine deaminase [ADA]) is the first ex vivo stem cell gene therapy approved by the European Medicines Agency (EMA), indicated as a single treatment for patients with ADA-severe combined immunodeficiency (ADA-SCID) who lack a suitable matched related bone marrow donor. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29625577", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can therapeutic levels of  Vedolizumab be found in the breast milk of nursing mothers following treatment for Inflammatory bowel disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28961712"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Vedolizumab is barely detectable in the breast milk of nursing mothers. measurements in breast milk after an infusion of the drug showed that levels did not surpass 480 ng/ml, which was roughly 1/100 of the comparable serum levels.", 
        "vedolizumab can be detected in the breast milk of nursing mothers. although more data are imperative, the concentrations of vedolizumab in breast milk are minute and are therefore unlikely to result in systemic or gastro-intestinal immune-suppression of the infant.", 
        "Vedolizumab can be detected in the breast milk of nursing mothers. Although more data are imperative, the concentrations of vedolizumab in breast milk are minute and are therefore unlikely to result in systemic or gastro-intestinal immune-suppression of the infant.", 
        "Vedolizumab can be detected in the breast milk of nursing mothers .\nAlthough more data are imperative , the concentrations of vedolizumab in breast milk are minute and are therefore unlikely to result in systemic or gastro-intestinal immune-suppression of the infant ."
      ], 
      "exact_answer": "no", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5c9f7bb6ecadf2e73f00003e", 
      "snippets": [
        {
          "offsetInBeginSection": 1086, 
          "offsetInEndSection": 1351, 
          "text": "Vedolizumab can be detected in the breast milk of nursing mothers. Although more data are imperative, the concentrations of vedolizumab in breast milk are minute and are therefore unlikely to result in systemic or gastro-intestinal immune-suppression of the infant.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961712", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1158, 
          "offsetInEndSection": 1356, 
          "text": "Although more data are imperative, the concentrations of vedolizumab in breast milk are minute and are therefore unlikely to result in systemic or gastro-intestinal immune-suppression of the infant.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961712", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 671, 
          "offsetInEndSection": 831, 
          "text": "Results\nVedolizumab was undetectable in breast milk in IBD patients before the first infusion of vedolizumab [n = 3] and in all of the healthy controls [n = 5].", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961712", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 916, 
          "offsetInEndSection": 1076, 
          "text": "However, on serial measurements in breast milk after an infusion, drug levels did not surpass 480 ng/ml, which was roughly 1/100 of the comparable serum levels.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961712", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 942, 
          "offsetInEndSection": 1192, 
          "text": "However, on serial measurements in breast milk after an infusion, drug levels did not surpass 480 ng/ml, which was roughly 1/100 of the comparable serum levels.<br><b>Conclusions</b>: Vedolizumab can be detected in the breast milk of nursing mothers.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961712", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 873, 
          "offsetInEndSection": 1033, 
          "text": "However, on serial measurements in breast milk after an infusion, drug levels did not surpass 480 ng/ml, which was roughly 1/100 of the comparable serum levels.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28961712", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is predicted using SURFY?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30373828"
      ], 
      "triples": [], 
      "ideal_answer": [
        "surfaceome predictor SURFY, based on machine learning."
      ], 
      "exact_answer": [
        [
          "surfaceome predictor"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5cb0e4a6ecadf2e73f00005b", 
      "snippets": [
        {
          "offsetInBeginSection": 412, 
          "offsetInEndSection": 526, 
          "text": "o enable analysis of the human surfaceome, we developed the surfaceome predictor SURFY, based on machine learning.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30373828", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which was the first adeno-associated virus vector gene therapy product approved in the United States?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30089698"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The first adeno-associated virus vector gene therapy product in the United States was Luxturna."
      ], 
      "exact_answer": [
        [
          "Luxturna"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c897555d558e5f232000009", 
      "snippets": [
        {
          "offsetInBeginSection": 1755, 
          "offsetInEndSection": 2009, 
          "text": "Gene therapy utilizing viral vectors has experienced recent success, culminating in U.S. Food and Drug Administration approval of the first adeno-associated virus vector gene therapy product in the United States: Luxturna for inherited retinal dystrophy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30089698", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is known about the gene MIR140?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21576357", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24973690", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28928081"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Chondrocyte-specific microRNA-140 regulates endochondral bone development and targets Dnpep to modulate bone morphogenetic protein signaling.\nOur findings showed the novel transcriptional role of miR140-5p in the expression of Nrf2 and miR-140-5p protected against Cisplatin induced oxidative stress by activating Nrf2-dependent antioxidant pathway, providing a potentially therapeutic target in acute kidney injury."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "5c8a8f56d558e5f23200000b", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 141, 
          "text": "Chondrocyte-specific microRNA-140 regulates endochondral bone development and targets Dnpep to modulate bone morphogenetic protein signaling.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576357", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1228, 
          "offsetInEndSection": 1456, 
          "text": "These results demonstrate that Mir140 is essential for normal endochondral bone development and suggest that the reduced BMP signaling caused by Dnpep upregulation plays a causal role in the skeletal defects of Mir140-null mice.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576357", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 831, 
          "offsetInEndSection": 902, 
          "text": "Transcripts associated with cartilage development (e.g., Acan, miR140) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24973690", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1703, 
          "offsetInEndSection": 1977, 
          "text": "Our findings showed the novel transcriptional role of miR140-5p in the expression of Nrf2 and miR-140-5p protected against Cisplatin induced oxidative stress by activating Nrf2-dependent antioxidant pathway, providing a potentially therapeutic target in acute kidney injury.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28928081", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which gene therapy treatment is FDA approved for retinal dystrophy?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30089698"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Luxturna is approved by the Food and Drug Administration (FDA) for the treatment of inherited retinal dystrophy."
      ], 
      "exact_answer": [
        [
          "Luxturna"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c89773ed558e5f23200000a", 
      "snippets": [
        {
          "offsetInBeginSection": 1755, 
          "offsetInEndSection": 2010, 
          "text": "Gene therapy utilizing viral vectors has experienced recent success, culminating in U.S. Food and Drug Administration approval of the first adeno-associated virus vector gene therapy product in the United States: Luxturna for inherited retinal dystrophy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30089698", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Salivary Cortisol is a biomarker for what disease/syndrome/condition?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23971022", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29455296", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30408721", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29747642", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23969030", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28375882", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19095358", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22812714", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20685855", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27686043", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23017499", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27014891", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25773457", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23332247", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21838298", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30488082"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Salivary Cortisol is a biomarker for stress", 
        "These results suggest that the saliva cortisol level is therefore a useful biomarker to evaluate the stress in AD patients.", 
        "Salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", 
        "Salivary cortisone , as a biomarker for psychosocial stress , is associated with state anxiety and heart rate .\nortisol as a stress biomarker"
      ], 
      "exact_answer": [
        [
          "stress"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c9fb428ecadf2e73f000041", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 108, 
          "text": "Salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30408721", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 55, 
          "offsetInEndSection": 84, 
          "text": "ortisol as a stress biomarker", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29455296", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 160, 
          "offsetInEndSection": 267, 
          "text": "The salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23971022", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1095, 
          "offsetInEndSection": 1364, 
          "text": "SUMMARY\nSalivary cortisol and cortisone can be used to assess cortisol excess, deficiency and hydrocortisone replacement, with salivary cortisone having the advantage of detection when serum cortisol levels are low and there is no interference from oral hydrocortisone.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28375882", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 840, 
          "offsetInEndSection": 1092, 
          "text": "Salivary cortisone is a superior marker of serum cortisol compared with salivary cortisol, specifically when serum cortisol is low and during hydrocortisone therapy when contamination of saliva may result in misleading salivary cortisol concentrations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28375882", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 76, 
          "text": "Salivary cortisol is frequently used as a biomarker of psychological stress.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19095358", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 618, 
          "offsetInEndSection": 893, 
          "text": "The present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an HPAA biomarker of stress in their experiments.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19095358", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 77, 
          "offsetInEndSection": 238, 
          "text": "However, psychobiological mechanisms, which trigger the hypothalamus-pituitary-adrenal axis (HPAA) can only indirectly be assessed by salivary cortisol measures.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19095358", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 52, 
          "text": "Salivary cortisol as a biomarker in stress research.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19095358", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 976, 
          "offsetInEndSection": 1181, 
          "text": "As a biomarker for depression, salivary cortisol VAR demonstrated an optimal cutoff point at 77.8% (AUC=0.94; 95% CI, 0.85-0.98), which is associated with a sensitivity of 82.1% and a specificity of 96.0%.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23969030", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 209, 
          "text": "Salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27686043", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 266, 
          "text": "BACKGROUND\nThe aim of this study was to evaluate salivary alpha-amylase (sAA), considered a non-invasive biomarker for sympathetic nervous system (SNS) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29747642", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 123, 
          "text": "Salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23017499", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1124, 
          "offsetInEndSection": 1385, 
          "text": "CONCLUSION\nSalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27014891", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 162, 
          "text": "PURPOSE\nCortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773457", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 267, 
          "offsetInEndSection": 504, 
          "text": "METHODS\nIn 323 children (5-10 years old) participating in the Belgian ChiBS study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23332247", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 72, 
          "text": "Cortisol is a classical biomarker for the stress levels of human beings.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21838298", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1588, 
          "offsetInEndSection": 1769, 
          "text": "Finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22812714", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 128, 
          "text": "Salivary cortisol as a biomarker in stress research.Salivary cortisol is frequently used as a biomarker of psychological stress. ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19095358", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What is the function of the cGAS pathway?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29169058", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30395807", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28137885", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28801534", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28920955", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28940468", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27648547", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26944200", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27902332"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The cGAS-STING pathway not only mediates protective immune defense against infection by a large variety of DNA-containing pathogens but also detects tumor-derived DNA and generates intrinsic antitumor immunity."
      ], 
      "exact_answer": [
        [
          "Immune defense"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c8aa082d558e5f23200000c", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 100, 
          "text": "Cyclic di-AMP (c-di-AMP) is a bacterial signaling nucleotide synthesized by several human pathogens.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29169058", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 296, 
          "text": "Cyclic GMP-AMP synthase (cGAS) has recently been identified as the primary protein that detects cytosolic double stranded DNA to invoke a type I interferon response. The cGAS pathway is vital in the recognition of DNA encoded viruses as well as self-DNA leaked from the nucleus of damaged cells. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30395807", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 887, 
          "offsetInEndSection": 1053, 
          "text": "These results indicate that activation of the cGAS pathway is important for intrinsic antitumor immunity and that cGAMP may be used directly for cancer immunotherapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28137885", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 881, 
          "offsetInEndSection": 1019, 
          "text": " this work identifies long DNA as the molecular entity stimulating the cGAS pathway upon cytosolic DNA challenge such as viral infections.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28801534", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 872, 
          "offsetInEndSection": 1155, 
          "text": "these data suggest that inactivation of the cGAS pathway plays a critical role in tumour progression, and reveal a direct link between hypoxia-responsive miRNAs and adaptive immune responses to the hypoxic tumour microenvironment, thus unveiling potential new therapeutic strategies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28920955", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 176, 
          "offsetInEndSection": 306, 
          "text": "dysregulation of the cGAS pathway is linked to autoimmune diseases while targeted stimulation may be of benefit in immunoncology. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28940468", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 299, 
          "offsetInEndSection": 510, 
          "text": "The cGAS-STING pathway not only mediates protective immune defense against infection by a large variety of DNA-containing pathogens but also detects tumor-derived DNA and generates intrinsic antitumor immunity. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27648547", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 890, 
          "offsetInEndSection": 1052, 
          "text": "our data indicate that the cGAS-STING pathway plays a role in the surveillance of HBV infection and may be exploited for development of novel anti-HBV strategies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27902332", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Does RUNX2 inhibit astrocyte differentiation?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27546532"
      ], 
      "triples": [], 
      "ideal_answer": [
        "No, RUNX2 promostes astrocyte differentiation."
      ], 
      "exact_answer": "no", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5c8fe71b0101eac87000000b", 
      "snippets": [
        {
          "offsetInBeginSection": 610, 
          "offsetInEndSection": 886, 
          "text": "The method was able to recapitulate experimentally validated cell-fate determinants, and validation of two predicted cell-fate determinants confirmed that overexpression of ESR1 and RUNX2 in mouse neural stem cells induces neuronal and astrocyte differentiation, respectively.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27546532", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are 5 key questions in human performance modeling?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29531424", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22005615"
      ], 
      "triples": [], 
      "ideal_answer": [
        "There are five key questions of human performance modeling: 1) Why we build models of human performance; 2) What the expectations of a good human performance model are; 3) What the procedures and requirements in building and verifying a human performance model are; 4) How we integrate a human performance model with system design; and 5) What the possible future directions of human performance modeling research are.", 
        "the five key questions of human performance modeling: 1) why we build models of human performance; 2) what the expectations of a good human performance model are; 3) what the procedures and requirements in building and verifying a human performance model are; 4) how we integrate a human performance model with system design; and 5) what the possible future directions of human performance modeling research are.", 
        "the five key questions of human performance modeling: 1) Why we build models of human performance; 2) What the expectations of a good human performance model are; 3) What the procedures and requirements in building and verifying a human performance model are; 4) How we integrate a human performance model with system design; and 5) What the possible future directions of human performance modeling research are.", 
        "the five key questions of human performance modeling: 1) Why we build models of human performance; 2) What the expectations of a good human performance model are; 3) What the procedures and requirements in building and verifying a human performance model are; 4) How we integrate a human performance model with system design; and 5) What the possible future directions of human performance modeling research are"
      ], 
      "exact_answer": [
        [
          "Why build models?"
        ], 
        [
          "What are the expectations of a good model?"
        ], 
        [
          "What are the procedures and requirements?"
        ], 
        [
          "How do we integrate a model with system design?"
        ], 
        [
          "What are the future directions of Human performance modeling?"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "5c9fb583ecadf2e73f000042", 
      "snippets": [
        {
          "offsetInBeginSection": 254, 
          "offsetInEndSection": 667, 
          "text": "the five key questions of human performance modeling: 1) Why we build models of human performance; 2) What the expectations of a good human performance model are; 3) What the procedures and requirements in building and verifying a human performance model are; 4) How we integrate a human performance model with system design; and 5) What the possible future directions of human performance modeling research are. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29531424", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 218, 
          "offsetInEndSection": 666, 
          "text": "This paper describes and summarizes the five key questions of human performance modeling: 1) Why we build models of human performance; 2) What the expectations of a good human performance model are; 3) What the procedures and requirements in building and verifying a human performance model are; 4) How we integrate a human performance model with system design; and 5) What the possible future directions of human performance modeling research are.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29531424", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 169, 
          "offsetInEndSection": 614, 
          "text": "We conducted a systematic review of the literature to address 5 key questions specific to this population: 1) What are the current national clinical practice recommendations and guidelines for depression screening; 2) What are the prevalence and predictors of screening; 3) How well do screening tools detect depression; 4) Does screening lead to diagnosis, treatment, and improved outcomes; and 5) What are the most effective treatment methods?", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22005615", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 271, 
          "offsetInEndSection": 719, 
          "text": "This paper describes and summarizes the five key questions of human performance modeling: 1) Why we build models of human performance; 2) What the expectations of a good human performance model are; 3) What the procedures and requirements in building and verifying a human performance model are; 4) How we integrate a human performance model with system design; and 5) What the possible future directions of human performance modeling research are. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29531424", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 177, 
          "offsetInEndSection": 982, 
          "text": "We conducted a systematic review of the literature to address 5 key questions specific to this population: 1) What are the current national clinical practice recommendations and guidelines for depression screening; 2) What are the prevalence and predictors of screening; 3) How well do screening tools detect depression; 4) Does screening lead to diagnosis, treatment, and improved outcomes; and 5) What are the most effective treatment methods?<br><b>METHODS</b>: We searched bibliographic databases for full-length articles published in English between 1990 and 2010 that addressed at least 1 of our key questions.<br><b>RESULTS</b>: We identified 5 clinical practice guidelines pertinent to question 1, and 12 systematic reviews or post-hoc analyses of pooled data that addressed questions 3 through 5.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22005615", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the mode of action of the Tc toxins?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/11286884", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15679840", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23870259", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24572368", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27571177", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28233068", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30232455"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The toxin complex (tc) genes of bacteria comprise a large and growing family whose mode of action remains obscure. Tc toxins are widely distributed among different gram-negative and gram-positive bacteria, where they act as pathogenicity factors. Tripartite Tc toxin complexes of bacterial pathogens perforate the host membrane and translocate toxic enzymes into the host cell, including in humans. The underlying mechanism is complex but poorly understood."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "5c98fcf0ecadf2e73f00002c", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 268, 
          "text": "Tc toxins secrete toxic enzymes into host cells using a unique syringe-like injection mechanism. They are composed of three subunits, TcA, TcB and TcC. TcA forms the translocation channel and the TcB-TcC heterodimer functions as a cocoon that shields the toxic enzyme.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30232455", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 98, 
          "text": "The toxin complex (tc) genes of Photorhabdus encode insecticidal, high molecular weight Tc toxins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11286884", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "The toxin complex (tc) genes of bacteria comprise a large and growing family whose mode of action remains obscure. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15679840", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 131, 
          "text": "Tc toxins are widely distributed among different gram-negative and gram-positive bacteria, where they act as pathogenicity factors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23870259", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 211, 
          "text": "Tripartite Tc toxin complexes of bacterial pathogens perforate the host membrane and translocate toxic enzymes into the host cell, including in humans. The underlying mechanism is complex but poorly understood. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24572368", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 236, 
          "text": "Tc toxins from pathogenic bacteria use a special syringe-like mechanism to perforate the host cell membrane and inject a deadly enzyme into the host cytosol. The molecular mechanism of this unusual injection system is poorly understood.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27571177", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 188, 
          "text": "Various bacterial toxins have potent insecticidal activity. Recently, the Toxin complexes (Tc's) of Photorhabdus and Xenorhabdus species have become an increased focus of current research.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28233068", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What does RUNX2 stand for?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19121369"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Runt related factor-2"
      ], 
      "exact_answer": [
        [
          "Runt related factor-2"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c8fe7cb0101eac87000000c", 
      "snippets": [
        {
          "offsetInBeginSection": 367, 
          "offsetInEndSection": 396, 
          "text": "Runt related factor-2 (Runx2)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19121369", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29413774"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The Cobb-Stainsby forefoot arthroplasty combines partial phalangectomy (Stainsby) with extensor tendon transfer to the metatarsal head (Cobb).", 
        "The Cobb-Stainsby forefoot arthroplasty combines partial phalangectomy (Stainsby) with extensor tendon transfer", 
        "The Cobb-Stainsby forefoot arthroplasty combines partial phalangectomy ( Stainsby ) with extensor tendon transfer to the metatarsal head ( Cobb ) .", 
        "The Cobb-Stainsby forefoot arthroplasty combines partial phalangectomy (Stainsby) with extensor tendon transfer to the metatarsal head (Cobb)"
      ], 
      "exact_answer": [
        [
          "foot"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c9ff25eecadf2e73f000043", 
      "snippets": [
        {
          "offsetInBeginSection": 131, 
          "offsetInEndSection": 274, 
          "text": "The Cobb-Stainsby forefoot arthroplasty combines partial phalangectomy (Stainsby) with extensor tendon transfer to the metatarsal head (Cobb). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29413774", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 130, 
          "offsetInEndSection": 272, 
          "text": "The Cobb-Stainsby forefoot arthroplasty combines partial phalangectomy (Stainsby) with extensor tendon transfer to the metatarsal head (Cobb).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29413774", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 138, 
          "offsetInEndSection": 280, 
          "text": "The Cobb-Stainsby forefoot arthroplasty combines partial phalangectomy (Stainsby) with extensor tendon transfer to the metatarsal head (Cobb).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29413774", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 119, 
          "offsetInEndSection": 261, 
          "text": "The Cobb-Stainsby forefoot arthroplasty combines partial phalangectomy (Stainsby) with extensor tendon transfer to the metatarsal head (Cobb).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29413774", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are cardenolides inhibitors of Na+/K+ ATPase?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30053394", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29683473", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30372816"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes,\nCardenolides have shown significant antitumor activity due to their ability to inhibit the Na+K+ATPase enzyme, and the expression of this enzyme is increased in tumor cells."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5c9906dcecadf2e73f00002f", 
      "snippets": [
        {
          "offsetInBeginSection": 257, 
          "offsetInEndSection": 493, 
          "text": ". Previously, we reported that a variety of cardenolides impart anti-transmissible gastroenteritis coronavirus (TGEV) activity in swine testicular (ST) cells, through targeting of the cell membrane sodium/potassium pump, Na+/K+-ATPase. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30053394", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 970, 
          "offsetInEndSection": 1092, 
          "text": ": We found evidence for low cardenolides by HPLC, but substantial toxicity when extracts were assayed on Na+ /K+ -ATPases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29683473", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 316, 
          "offsetInEndSection": 490, 
          "text": "Cardenolides have shown significant antitumor activity due to their ability to inhibit the Na+K+ATPase enzyme, and the expression of this enzyme is increased in tumor cells. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30372816", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can antisense threapy be used for Huntington's disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22726826"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes, antisense oligonucleotide therapy has been shown to lower Huntingtin mRNA levels and be beneficial against Huntington's disease."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5c900779ecadf2e73f000001", 
      "snippets": [
        {
          "offsetInBeginSection": 89, 
          "offsetInEndSection": 290, 
          "text": "In this issue of Neuron, Kordasiewicz et\u00a0al. (2012) show the benefit of transient antisense oligonucleotide (ASO) therapy to degrade Huntingtin mRNA and elicit sustained therapeutic benefit in HD mice.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22726826", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 84, 
          "text": "\"Huntingtin holiday\": progress toward an antisense therapy for Huntington's disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22726826", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What are acoustic reported genes used to detect?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29300010"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Acoustic reporter genes are genetic constructs that allow bacterial gene expression to be visualized in vivo using ultrasound.", 
        "Here we introduce acoustic reporter genes, which are genetic constructs that allow bacterial gene expression to be visualized in vivo using ultrasound,", 
        "Here we introduce acoustic reporter genes, which are genetic constructs that allow bacterial gene expression to be visualized in vivo using ultrasound", 
        "acoustic reporter genes, which are genetic constructs that allow bacterial gene expression to be visualized in vivo using ultrasound,", 
        "acoustic reporter genes , which are genetic constructs that allow bacterial gene expression to be visualized in vivo using ultrasound ,"
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "5ca9f932ecadf2e73f000054", 
      "snippets": [
        {
          "offsetInBeginSection": 526, 
          "offsetInEndSection": 659, 
          "text": "acoustic reporter genes, which are genetic constructs that allow bacterial gene expression to be visualized in vivo using ultrasound,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29300010", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is a lipin 1 protein doing?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29457836", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30028636", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30092116"
      ], 
      "triples": [], 
      "ideal_answer": [
        "As a lipin family founding member, lipin1 exerts dual functions as a phosphatidate phosphatase enzyme and/or a co-transcriptional regulator in lipid metabolism. In fact, it is also involved in many other cell processes."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "5ca3bfd7ecadf2e73f00004b", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 193, 
          "text": "Lipin 1 regulates glycerolipid homeostasis by acting as a phosphatidic acid phosphohydrolase (PAP) enzyme in the triglyceride-synthesis pathway and by regulating transcription factor activity. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30028636", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 219, 
          "text": "As a lipin family founding member, lipin1 exerts dual functions as a phosphatidate phosphatase enzyme and/or a co-transcriptional regulator in lipid metabolism. In fact, it is also involved in many other cell processes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30092116", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1381, 
          "offsetInEndSection": 1409, 
          "text": "lipogenic regulator lipin 1 ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29457836", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which company produces patisiran?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30251172"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Patisiran has been developed by Alnylam Pharmaceuticals."
      ], 
      "exact_answer": [
        [
          "Alnylam Pharmaceuticals"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c900b9eecadf2e73f000004", 
      "snippets": [
        {
          "offsetInBeginSection": 426, 
          "offsetInEndSection": 722, 
          "text": "Patisiran has been developed by Alnylam Pharmaceuticals; it was recently approved in the USA for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis (hATTR) in adults and subsequently approved in the EU for the treatment of hATTR in adults with stage 1 or 2 polyneuropathy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30251172", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What protein is recruited by Crumbs to regulate tracheal development?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25065756", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21172808"
      ], 
      "triples": [], 
      "ideal_answer": [
        "In Drosophila, stellate-shaped tracheal terminal cells make seamless tubes, Early endocytosis maintains normal steady-state levels of Crumbs, which recruits apical phosphorylated (active) Moesin (Moe), which in turn regulates seamless tube shape in the development of the trachea."
      ], 
      "exact_answer": [
        [
          "moesin (Moe)"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5caa0247ecadf2e73f000055", 
      "snippets": [
        {
          "offsetInBeginSection": 1144, 
          "offsetInEndSection": 1320, 
          "text": "We propose that early endocytosis maintains normal steady-state levels of Crumbs, which recruits apical phosphorylated (active) Moe, which in turn regulates seamless tube shape", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25065756", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 717, 
          "offsetInEndSection": 962, 
          "text": "There, Crb, acting in parallel with the epidermal growth factor receptor (Egfr) pathway, is required for tracheal cell apical constriction and for organising an actomyosin complex, which we propose is mediated by Crb recruitment of moesin (Moe).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21172808", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is collagen matrix of human articular cartilage changing with disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27384346", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20488735", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18991091"
      ], 
      "triples": [], 
      "ideal_answer": [
        "No,\nThe collagen matrix of human articular cartilage is an essentially permanent structure that has no significant turnover in adults, even with the occurrence of disease."
      ], 
      "exact_answer": "no", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5ca5127eecadf2e73f00004c", 
      "snippets": [
        {
          "offsetInBeginSection": 943, 
          "offsetInEndSection": 1110, 
          "text": "The collagen matrix of human articular cartilage is an essentially permanent structure that has no significant turnover in adults, even with the occurrence of disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27384346", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1055, 
          "offsetInEndSection": 1164, 
          "text": "the chondrocytes in ageing articular cartilage have limited capacity to turnover the interterritorial matrix.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18991091", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "Type II collagen is a major component of articular cartilage and its breakdown is a key feature of osteoarthritis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20488735", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is ustekinumab a polyclonal antibody?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29164954"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Ustekinumab is a human monoclonal IgG1 antibody targeting the p40-subunit shared by interleukin (IL)12 and IL-23."
      ], 
      "exact_answer": "no", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5c9162b5ecadf2e73f00000e", 
      "snippets": [
        {
          "offsetInBeginSection": 5, 
          "offsetInEndSection": 177, 
          "text": "Ustekinumab, a human monoclonal IgG1 antibody targeting the p40-subunit shared by interleukin (IL)12 and IL-23, represents a potential treatment for atopic dermatitis (AD).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29164954", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Where in the body, is ghrelin secreted?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29392854", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15648018", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22231739", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17096064", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12176667", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19129426", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19009647", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26019019", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18350524", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16254526", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17251274", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21035199", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17983856", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17101319", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27376422", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24806082", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17646723", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12352514"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Ghrelin, an orexigenic peptide, is secreted from endocrine cells in the gastric mucosa.", 
        "BACKGROUND: Ghrelin, an orexigenic peptide, is secreted from endocrine cells in the gastric mucosa.", 
        "ghrelin, an orexigenic peptide, is secreted from endocrine cells in the gastric mucosa.", 
        "Ghrelin , an orexigenic peptide , is secreted from endocrine cells in the gastric mucosa ."
      ], 
      "exact_answer": [
        [
          "stomach"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5caa06d0ecadf2e73f000056", 
      "snippets": [
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 99, 
          "text": "Ghrelin, an orexigenic peptide, is secreted from endocrine cells in the gastric mucosa.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29392854", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 64, 
          "text": "Ghrelin is a recently described hormone secreted by the stomach.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15648018", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "BACKGROUND\nGhrelin is secreted mainly in the stomach and plays a role in food intake regulation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22231739", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 109, 
          "text": "BACKGROUND\nGhrelin is a body weight-regulating peptide produced and secreted primarily by the gastric mucosa.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17096064", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1533, 
          "offsetInEndSection": 1935, 
          "text": "These results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12176667", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 66, 
          "text": "Ghrelin is a 28-amino acid peptide secreted mainly by the stomach.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19129426", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 132, 
          "text": "Ghrelin is primarily secreted from the stomach and has been implicated in the coordination of eating behavior and weight regulation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19009647", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 343, 
          "offsetInEndSection": 515, 
          "text": "Most of the ghrelin produced in the body is secreted in the stomach, but it is also expressed in the hypothalamus, pituitary, pancreas, intestine, kidney, heart and gonads.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18350524", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 186, 
          "text": "OBJECTIVES\nGhrelin, a recently discovered hormone mainly secreted by the stomach, has several metabolic functions including regulation of food intake, energy homeostasis and body weight.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16254526", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 142, 
          "text": "PURPOSE\nGhrelin is mainly secreted from the stomach and plays a role in appetite, weight gain, and the promotion of a positive energy balance.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26019019", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 224, 
          "text": "Ghrelin, the only known orexigenic gut hormone, is secreted mainly from the stomach, increases with fasting and before meal initiation in humans and rats, and increases food intake after central or peripheral administration.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17251274", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 66, 
          "text": "Ghrelin is a peptide hormone produced and secreted in the stomach.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21035199", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 299, 
          "offsetInEndSection": 392, 
          "text": "Ghrelin secreted by the stomach stimulates the afferent vagus nerve and promotes food intake.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17983856", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 80, 
          "text": "BACKGROUND & AIMS\nGhrelin is secreted by the stomach and stimulates food intake.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17101319", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 97, 
          "text": "Ghrelin is a gut peptide composed of 28 amino acids mostly secreted in the gastric fundus mucosa.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27376422", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 113, 
          "text": "BACKGROUND\nA wide variety of functions has been attributed to ghrelin, a peptide hormone secreted in the stomach.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24806082", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 104, 
          "text": "OBJECTIVE\nGhrelin is a hormone secreted mainly in the stomach which stimulates appetite and food intake.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17646723", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 125, 
          "text": "Ghrelin and feedback systems.Ghrelin is produced primarily in the stomach in response to hunger, and circulates in the blood. ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17983856", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 117, 
          "text": "<b>BACKGROUND</b>: Ghrelin is a body weight-regulating peptide produced and secreted primarily by the gastric mucosa.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17096064", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1533, 
          "offsetInEndSection": 1939, 
          "text": "These results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.<br>", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12176667", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 159, 
          "text": "<b>BACKGROUND</b>: Ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12352514", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 140, 
          "text": "Ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12352514", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 98, 
          "text": "Ghrelin is a body weight-regulating peptide produced and secreted primarily by the gastric mucosa.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17096064", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List the ERM proteins.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29329782", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29311472", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29777033"
      ], 
      "triples": [], 
      "ideal_answer": [
        "ezrin\nradixin\nmoesin"
      ], 
      "exact_answer": [
        [
          "ezrin"
        ], 
        [
          "radixin"
        ], 
        [
          "moesin"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "5ca64b5becadf2e73f000051", 
      "snippets": [
        {
          "offsetInBeginSection": 423, 
          "offsetInEndSection": 458, 
          "text": "ezrin/radixin/moesin (ERM) proteins", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29329782", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 491, 
          "offsetInEndSection": 531, 
          "text": "ezrin, radixin and moesin (ERM proteins)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29311472", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 205, 
          "offsetInEndSection": 240, 
          "text": "Ezrin/radixin/moesin (ERM) proteins", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29777033", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is epitranscriptomics?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29671387"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Epitranscriptomics is the fast expanding area of RNA modifications."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "5c922bc3ecadf2e73f000013", 
      "snippets": [
        {
          "offsetInBeginSection": 1047, 
          "offsetInEndSection": 1191, 
          "text": "Here we provide a perspective on necessary and expected developments in the fast expanding area of RNA modifications, termed epitranscriptomics.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29671387", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is resistin?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29278852", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12660880", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26729407", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30353146", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14644422", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18417718", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24780007", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18191042", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14962997", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19095472", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23981771", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29937317", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27079485", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15103228", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19024936"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The adipocyte-secreting adipokine, resistin, may play a critical role in the modulation of inflammatory diseases.", 
        "Resistin, a pro-inflammatory cytokine,"
      ], 
      "exact_answer": [
        [
          "adipokine"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c840782617e120c34000006", 
      "snippets": [
        {
          "offsetInBeginSection": 641, 
          "offsetInEndSection": 800, 
          "text": "Resistin, a pro-inflammatory cytokine, is predictive of atherosclerosis and poor clinical outcomes in patients with coronary artery disease and ischemic stroke", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29278852", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 253, 
          "offsetInEndSection": 394, 
          "text": "Leptin, adiponectin, and resistin are the most studied adipokines which play important roles in the regulation of cardiovascular homeostasis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29278852", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 90, 
          "text": "Resistin is a recently discovered hormone that is exclusively expressed in adipose tissue.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12660880", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "Resistin is a secreted adipose tissue hormone that belongs to the resistin-like molecule family.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14644422", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 134, 
          "text": "Resistin is known as an adipocyte-specific secretory hormone that can cause insulin resistance and decrease adipocyte differentiation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18417718", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 101, 
          "text": "OBJECTIVES\nResistin is an adipocytokine that has been related to inflammation and insulin resistance.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24780007", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 90, 
          "text": "Resistin, an adipocyte-secreted factor, is known to be elevated in breast cancer patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26729407", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 137, 
          "text": "Resistin is an adipokine that induces insulin resistance in mice; serum concentrations are decreased by fasting and increased by feeding.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18191042", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 120, 
          "text": "Resistin is an adipose-derived hormone that has been proposed as a link among obesity, insulin resistance, and diabetes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14962997", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 90, 
          "text": "The adipokine resistin has been proposed to link obesity, insulin resistance and diabetes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30353146", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 135, 
          "text": "OBJECTIVE\nResistin is a secreted factor that is elevated in rheumatoid arthritis (RA) and believed to drive joint inflammation in vivo.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19095472", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 132, 
          "text": "Resistin is a circulating mediator of insulin resistance mainly expressed in human monocytes and responsive to inflammatory stimuli.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23981771", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 102, 
          "text": "BACKGROUND\nResistin is an immunometabolic mediator that is elevated in several inflammatory disorders.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29937317", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 170, 
          "text": "Pituitary resistin gene expression: effects of age, gender and obesity.Resistin is a new adipocytokine which is expressed in rat, mouse and possibly human adipose tissue. ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15103228", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 193, 
          "offsetInEndSection": 278, 
          "text": "Leptin belongs to the adipokine family, which also contains adiponectin and resistin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19024936", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is Pim-1 a protein phosphatase?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29399171", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29355758"
      ], 
      "triples": [], 
      "ideal_answer": [
        "No,\nPim-1 is a kinase and not a phosphatase."
      ], 
      "exact_answer": "no", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5cb37f76ecadf2e73f00005c", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 149, 
          "text": "Pim-1 proto-oncogene, serine/threonine kinase (PIM-1) phosphorylates a series of substrates to exert its oncogenic function in numerous malignancies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29399171", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 208, 
          "text": "The Pim1 serine/threonine kinase is associated with multiple cellular functions including proliferation, survival, differentiation, apoptosis, tumorigenesis, immune regulation and inflammation in vertebrates.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355758", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Name three binding partners of cofilin 2.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28886070", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19752190", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25373779"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Cofilin 2 can bind miR-201a, the protein 14-3-3, and ATP/ADP-Pi-actin filaments."
      ], 
      "exact_answer": [
        [
          "miR-301a"
        ], 
        [
          "14-3-3"
        ], 
        [
          "ATP/ADP-Pi-actin filaments"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "5c9007460101eac870000012", 
      "snippets": [
        {
          "offsetInBeginSection": 459, 
          "offsetInEndSection": 642, 
          "text": "Cofilin-2 (Cfl2) was identified as one of the potential targets of miR-301a using prediction databases, which we validated by luciferase assay and mutation of predicted binding sites.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28886070", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 437, 
          "offsetInEndSection": 738, 
          "text": "In contrast to other isoforms, cofilin-2 efficiently binds and disassembles both ADP- and ATP/ADP-Pi-actin filaments. We mapped surface-exposed cofilin-2-specific residues required for ATP-actin binding and propose that these residues function as an \"actin nucleotide-state sensor\" among ADF/cofilins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25373779", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the function of GvpA?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28898511", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25648404", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7683649", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1282192", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22941504", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9094221", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22580065"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Gas vesicles are proteinaceous, gas-filled nanostructures produced by some bacteria and archaea. The hydrophobic major structural protein GvpA forms the ribbed gas vesicle wall.", 
        "The gas vesicle wall is solely formed of proteins with the two major components, GvpA and GvpC, and", 
        "The gas vesicle wall is solely formed of proteins with the two major components, GvpA and GvpC, and seven additional accessory proteins are also involved.", 
        "The gas vesicle wall is solely formed of proteins with the two major components, GvpA and GvpC,", 
        "the gas vesicle wall is solely formed of proteins with the two major components, gvpa and gvpc,"
      ], 
      "exact_answer": [
        [
          "GvpA forms the gas vesicle wall"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5ca9f846ecadf2e73f000053", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 177, 
          "text": "Gas vesicles are proteinaceous, gas-filled nanostructures produced by some bacteria and archaea. The hydrophobic major structural protein GvpA forms the ribbed gas vesicle wall.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28898511", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 801, 
          "offsetInEndSection": 898, 
          "text": " The gas vesicle wall is solely formed of proteins with the two major components, GvpA and GvpC, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25648404", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 191, 
          "offsetInEndSection": 345, 
          "text": "The wall of these gas vesicles is freely permeable to gas molecules and is composed of a small hydrophobic protein, GvpA, which forms a single-layer wall.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22941504", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 101, 
          "text": "Gas vesicles are intracellular, microbial flotation devices that consist of mainly one protein, GvpA.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9094221", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 97, 
          "text": "Modeling of the major gas vesicle protein, GvpA: from protein sequence to vesicle wall structure.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22580065", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 205, 
          "offsetInEndSection": 364, 
          "text": "Gas vesicle production and the expression of the gvpA gene encoding the major gas vesicle protein, GvpA, was monitored in each Haloferax volcanii transformant.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1282192", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 134, 
          "text": "Analysis of gas vesicle gene expression in Haloferax mediterranei reveals that GvpA and GvpC are both gas vesicle structural proteins.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7683649", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What is a SMR based BCI?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29075937", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30063219", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26891350", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30414824", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25147518", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26736445", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21436515", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24080080", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24835634"
      ], 
      "triples": [], 
      "ideal_answer": [
        "An SMR based BCI is a SensoriMotor Rhythm Based brain-Computer Interface (BCI). It is an alternative communication system between the human brain and an output device and is controlled by a sensorimotor rhythm (SMR), a type of brain wave.", 
        "Many Brain Computer Interface (BCI) and neurofeedback studies have investigated the impact of sensorimotor rhythm (SMR)"
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "5c521c8c7e3cb0e231000007", 
      "snippets": [
        {
          "offsetInBeginSection": 395, 
          "offsetInEndSection": 458, 
          "text": " sensorimotor rhythm-based brain-computer interfaces (SMR-BCI) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29075937", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 209, 
          "offsetInEndSection": 403, 
          "text": "Here, we studied the immediate and therapeutic effects of BCI-based training to control pre-movement sensorimotor rhythm (SMR) amplitude on robot-assisted finger extension in people with stroke.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30063219", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 404, 
          "offsetInEndSection": 482, 
          "text": " Especially for BCIs based on the modulation of the Sensorimotor Rhythm (SMR) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26891350", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 5, 
          "offsetInEndSection": 119, 
          "text": "Brain Computer Interface (BCI) and neurofeedback studies have investigated the impact of sensorimotor rhythm (SMR)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30414824", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 111, 
          "text": "Modulation of sensorimotor rhythms (SMR) was suggested as a control signal for brain-computer interfaces (BCI).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25147518", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 104, 
          "text": "Sensorimotor rhythm (SMR) based Brain-Computer Interfaces (BCI) typically require lengthy user training.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26736445", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 310, 
          "text": "All brain-computer interface (BCI) groups that have published results of studies involving a large number of users performing BCI control based on the voluntary modulation of sensorimotor rhythms (SMR) report that BCI control could not be achieved by a non-negligible number of subjects (estimated 20% to 25%).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21436515", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 236, 
          "text": "OBJECTIVE\nConnect-Four, a new sensorimotor rhythm (SMR) based brain-computer interface (BCI) gaming application, was evaluated by four severely motor restricted end-users; two were in the locked-in state and had unreliable eye-movement.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24080080", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 192, 
          "text": "OBJECTIVE\nIt is well known that to acquire sensorimotor (SMR)-based brain-computer interface (BCI) control requires a training period before users can achieve their best possible performances.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24835634", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is myc a tumour suppressor gene?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27532209", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27880072", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28430012", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28833404"
      ], 
      "triples": [], 
      "ideal_answer": [
        "No,\r\nMyc is a proto-oncogene."
      ], 
      "exact_answer": "no", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5cb38a56ecadf2e73f00005e", 
      "snippets": [
        {
          "offsetInBeginSection": 255, 
          "offsetInEndSection": 374, 
          "text": "oncogenic Myc, a master transcription factor that turns on anabolic metabolism to promote cell growth in many cancers. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27532209", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 634, 
          "offsetInEndSection": 649, 
          "text": "he MYC oncogene", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27880072", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 653, 
          "offsetInEndSection": 686, 
          "text": " the proto-oncogene protein c-MYC", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28430012", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 90, 
          "offsetInEndSection": 188, 
          "text": "however, other genes such as the proto-oncogene c-Myc are promising targets for anticancer therapy", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28833404", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which syndrome is associated to SAMHD1 gene mutations?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29583030"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Mutations in the SAMHD1 gene that cause the severe autoimmune disease, Aicardi-Goutieres syndrome (AGS)."
      ], 
      "exact_answer": [
        [
          "Aicardi-Goutieres syndrome"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5c93e8bdecadf2e73f00001c", 
      "snippets": [
        {
          "offsetInBeginSection": 211, 
          "offsetInEndSection": 413, 
          "text": "Its emerging role as an effector of innate immunity is affirmed by mutations in the SAMHD1 gene that cause the severe autoimmune disease, Aicardi-Goutieres syndrome (AGS) and that are linked to cancer. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29583030", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List proteins with RING domain.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29187402", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29107100", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29432170", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29426838", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29324855", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29471350", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29295817", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29320607", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29367421"
      ], 
      "triples": [], 
      "ideal_answer": [
        "RING1\nTRIM proteins\nTRAF6 \nUHRF1\nMARCH7\nSINA\nBRCA1"
      ], 
      "exact_answer": [
        [
          "RING1"
        ], 
        [
          "TRIM proteins"
        ], 
        [
          "TRAF6"
        ], 
        [
          "UHRF1"
        ], 
        [
          "MARCH7"
        ], 
        [
          "SINA"
        ], 
        [
          "BRCA1"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "5c990afbecadf2e73f000030", 
      "snippets": [
        {
          "offsetInBeginSection": 512, 
          "offsetInEndSection": 581, 
          "text": " The RING domain of RING1 was required for its E3 Ub ligase activity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29187402", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 249, 
          "offsetInEndSection": 398, 
          "text": " The TRIM proteins are classically characterized by the presence of an amino-terminal RING domain and a B-box domain followed by a coiled coil domain", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29107100", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 217, 
          "offsetInEndSection": 311, 
          "text": "the detailed mechanism by which the TRAF6 RING dimer promotes ubiquitin transfer was unknown. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29432170", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 77, 
          "text": "RING ubiquitin E3 ligases enclose a RING domain for ubiquitin ligase activity", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29324855", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 917, 
          "offsetInEndSection": 935, 
          "text": " UHRF1 RING domain", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29471350", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 282, 
          "offsetInEndSection": 336, 
          "text": " MARCH7, a RING domain-containing ubiquitin E3 ligase,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29295817", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 151, 
          "text": "Seven in absentia (SINA) protein is one subgroup of ubiquitin ligases possessing an N-terminal cysteine-rich really interesting new gene (RING) domain,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29320607", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 136, 
          "offsetInEndSection": 179, 
          "text": "The BRCA1 RING domain is a ubiquitin ligase", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29367421", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What conditions are associated with mutations in the gene FAAH?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22442717", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22912404", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20942817", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20098695", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12060782", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10764768", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27327781"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Human FAAH gene mutations are associated with increased body weight and obesity. Results suggest that genetic mutations in FAAH may constitute important risk factors for problem drug use and support a potential link between functional abnormalities in the endogenous cannabinoid system and drug abuse and dependence.\nresearch on the genetic modulation of pain has already identified variants in these genes, relative to pain, which may facilitate the pharmacogenetic assessments of new analgesics."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "5c9d170cecadf2e73f000032", 
      "snippets": [
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 225, 
          "text": "FAAH (fatty acid amide hydrolase), primarily expressed in the liver, hydrolyzes the endocannabinoids fatty acid ethanolamides (FAA). Human FAAH gene mutations are associated with increased body weight and obesity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22442717", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 145, 
          "offsetInEndSection": 225, 
          "text": "Human FAAH gene mutations are associated with increased body weight and obesity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22442717", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 98, 
          "offsetInEndSection": 161, 
          "text": "whereas mutations in FAAH are associated with obesity in humans", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22912404", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 907, 
          "offsetInEndSection": 1162, 
          "text": "Collectively, these results suggest that genetic mutations in FAAH may constitute important risk factors for problem drug use and support a potential link between functional abnormalities in the endogenous cannabinoid system and drug abuse and dependence.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12060782", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1817, 
          "offsetInEndSection": 2082, 
          "text": "This is the first study to document that FAAH 385 A mutant alleles have a direct effect on elevated plasma levels of anandamide and related NAEs in humans. These biomarkers may indicate risk for severe obesity and may suggest novel ECS obesity treatment strategies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20098695", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1313, 
          "offsetInEndSection": 1769, 
          "text": "nerve growth factor (NGFB), its tyrosine kinase receptor (NTRK1) and the fatty acid amide hydrolase (FAAH) have become targets of interest. For most of these genes, functional variants have been associated with neuro-psychiatric disorders and not yet with analgesia. However, research on the genetic modulation of pain has already identified variants in these genes, relative to pain, which may facilitate the pharmacogenetic assessments of new analgesics.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20942817", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the results of mutations in the gene autoimmune regulator?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29150834", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29427825", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29437776", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29666621"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Autoimmune-polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a primary immunodeficiency caused by mutations in the autoimmune regulator gene (AIRE)"
      ], 
      "exact_answer": [
        [
          "Autoimmune-polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5cb39707ecadf2e73f000060", 
      "snippets": [
        {
          "offsetInBeginSection": 296, 
          "offsetInEndSection": 456, 
          "text": "a rare inherited disorder called autoimmune polyendocriopathy candidiasis ectodermal dystrophy (APECED) caused by mutations in autoimmune regulator (AIRE) gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29150834", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 338, 
          "offsetInEndSection": 559, 
          "text": "The crucial role played by AIRE in central immune tolerance emerged in the studies on the pathogenesis of Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy, a rare inherited polyendocrine/autoimmune disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29427825", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 258, 
          "text": "Autoimmune polyendocrine syndrome type 1 (APS-1; OMIM #240300), also referred to as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), is a rare monogenic autoimmune disorder caused by mutations in the autoimmune regulator (AIRE) gene. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29437776", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 161, 
          "text": "Autoimmune-polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a primary immunodeficiency caused by mutations in the autoimmune regulator gene (AIRE)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29666621", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is CD63 an exosomal marker?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28346015", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28819811", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28770472"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes,\nCD63 is a exosomal marker"
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5cb3a2dd99d1e53537000001", 
      "snippets": [
        {
          "offsetInBeginSection": 701, 
          "offsetInEndSection": 746, 
          "text": "f exosome marker proteins (e.g., CD63, Alix) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28770472", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 427, 
          "offsetInEndSection": 513, 
          "text": " CD63 levels and acetylcholinesterase (AChE) activity were used as markers of exosome,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28819811", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 399, 
          "offsetInEndSection": 475, 
          "text": " The results demonstrated these exosomes all expressed CD9, CD63, CD81, Alix", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28346015", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is subdural empyema a complication of sinusitis?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29404826", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29682134", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30014307", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29131135", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12521560", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7810468", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16777239", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9951090", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12172943", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12402493", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28806018", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16462969", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9217340", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17182345", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22030191", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25437686"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes, subdural empyema can be a complication of sinusitis"
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5ca0c81eecadf2e73f000047", 
      "snippets": [
        {
          "offsetInBeginSection": 19, 
          "offsetInEndSection": 180, 
          "text": "Acute and chronic sinusitis can give rise to a wide array of intracranial and orbital complications. These complications include brain abscess, subdural empyema,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29404826", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 170, 
          "offsetInEndSection": 323, 
          "text": " A computed tomography scan showed bilateral paranasal sinus disease, and magnetic resonance imaging showed a right frontal abscess and subdural empyema.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29682134", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 70, 
          "text": "Frontal sinusitis complicated by a brain abscess and subdural empyema.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29682134", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 204, 
          "offsetInEndSection": 292, 
          "text": "In older children, sinusitis and otitis media are usually the source for subdural empyem", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30014307", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 76, 
          "text": "Subdural empyema as a complication of sinusitis in the pediatric population.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16777239", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 2077, 
          "offsetInEndSection": 2182, 
          "text": "Second, subdural empyema appears to arise in the setting of subacute rather than acute frontal sinusitis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16777239", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 358, 
          "offsetInEndSection": 514, 
          "text": "Subdural empyema is a rare but potentially life-threatening complication following paranasal sinusitis and should be considered as a neurological emergency.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29131135", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 49, 
          "text": "[Subdural empyema as a complication of sinusitis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9951090", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 83, 
          "text": "INTRODUCTION\nSubdural empyema is an uncommon but serious complication of sinusitis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12172943", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 185, 
          "offsetInEndSection": 318, 
          "text": "Intracranial subdural empyema is most frequently a complication of sinusitis or, less frequently, otitis or neurosurgical procedures.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12521560", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 397, 
          "offsetInEndSection": 471, 
          "text": "Subdural empyema is a rare complication of sinusitis although very severe.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12402493", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 65, 
          "text": "Subdural empyema is a rare complication of sinusitis in children.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16462969", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 162, 
          "text": "Subdural empyema is a rare but serious complication of paranasal sinusitis which may result in death or permanent disability in a significant proportion of cases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9217340", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 727, 
          "offsetInEndSection": 850, 
          "text": "We report a case of subdural empyema secondary to frontal sinusitis in an otherwise healthy immunocompetent adolescent boy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22030191", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 191, 
          "offsetInEndSection": 309, 
          "text": "Subdural empyema is a rare but life-threatening complication of paranasal sinusitis, otitis media, or mastoid disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28806018", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 82, 
          "text": "Wolf in Sheep's Clothing Subdural Empyema: A Rare Complication of Acute Sinusitis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28806018", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 124, 
          "text": "Interhemispheric and Infratentorial Subdural Empyema with Preseptal Cellulitis as Complications of Sinusitis: A Case Report.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29131135", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 196, 
          "text": "Subdural empyema as a complication of sinusitis in the pediatric population.<AbstractText Label=\"OBJECTIVE\" NlmCategory=\"OBJECTIVE\">Sinusitis is a rare cause of intracranial infection in children. ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16777239", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 49, 
          "text": "[Subdural empyema as a complication of sinusitis. ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9951090", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 202, 
          "offsetInEndSection": 335, 
          "text": "Intracranial subdural empyema is most frequently a complication of sinusitis or, less frequently, otitis or neurosurgical procedures. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12521560", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 288, 
          "text": "Streptococcus pluranimalium: A novel human pathogen?<AbstractText Label=\"INTRODUCTION\" NlmCategory=\"BACKGROUND\">We present the first case of a subdural empyema caused by Streptococcus pluranimalium, in a healthy adolescent male as a possible complication of subclinical frontal sinusitis. ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25437686", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1043, 
          "offsetInEndSection": 1283, 
          "text": "<AbstractText Label=\"DISCUSSION\" NlmCategory=\"CONCLUSIONS\">The diagnosis of subdural empyema as a complication of asymptomatic sinusitis in an immunocompetent patient with no history of fever or upper respiratory symptoms was unanticipated. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25437686", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2329, 
          "offsetInEndSection": 2434, 
          "text": "Second, subdural empyema appears to arise in the setting of subacute rather than acute frontal sinusitis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16777239", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 193, 
          "text": "Bifrontal decompressive craniectomy for acute subdural empyema.<AbstractText Label=\"INTRODUCTION\" NlmCategory=\"BACKGROUND\">Subdural empyema is an uncommon but serious complication of sinusitis. ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12172943", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 482, 
          "offsetInEndSection": 638, 
          "text": "Subdural empyema is a rare but potentially life-threatening complication following paranasal sinusitis and should be considered as a neurological emergency. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29131135", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 385, 
          "offsetInEndSection": 530, 
          "text": "We present a patient with subdural empyema in whom the diagnosis was delayed, followed by a discussion of suppurative complications of sinusitis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17182345", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 374, 
          "offsetInEndSection": 607, 
          "text": "<AbstractText Label=\"CASE REPORT\" NlmCategory=\"METHODS\">We report an unusual case of sinusitis-associated acute subdural empyema in a 13-year-old patient, presenting in a catastrophic manner with acutely raised intracranial pressure. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12172943", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 272, 
          "offsetInEndSection": 475, 
          "text": "The symptoms of subdural empyema may be mild and may be the same as those associated with sinusitis, or the infection may result in alteration of the level of consciousness and focal neurologic deficits.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7810468", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 224, 
          "offsetInEndSection": 335, 
          "text": "We report the clinical and radiological course of an adolescent with a subdural empyema secondary to sinusitis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16462969", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 502, 
          "offsetInEndSection": 602, 
          "text": "We report two cases of subdural empyema secondary to sinusitis in persons without impaired immunity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9951090", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 48, 
          "text": "Subdural empyema as a complication of sinusitis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9951090", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 102, 
          "offsetInEndSection": 246, 
          "text": "Furthermore, subdural empyema usually is related to sinus infections, particularly those caused by Streptococcus milleri, an anaerobic organism.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9951090", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 70, 
          "text": "Subdural empyema is an uncommon but serious complication of sinusitis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12172943", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is aphasia?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26999324", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28691196"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Aphasia  is an inability to comprehend or formulate language because of damage to specific brain regions."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "5c9fb2aaecadf2e73f00003f", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 109, 
          "text": "Aphasia, the language disorder following brain damage, is frequently accompanied by deficits of working memor", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26999324", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 82, 
          "text": "People with aphasia (PWA) use pantomime, gesture in absence of speech,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691196", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Anaplasma phagocytophilum is an obligate gram-negative, intracellular bacterium, yes  or no", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29398602", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30217516"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Anaplasma phagocytophilum is an obligate gram-negative, intracellular bacterium and causes anaplasmosis", 
        "The genus Anaplasma belonging to the Anaplasmataceae family (order Rickettsiales) comprises obligate intracellular Gram-negative bacteria of veterinary and public health importance. nov."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5c98ac7fecadf2e73f00002b", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 441, 
          "text": "The genus Anaplasma belonging to the Anaplasmataceae family (order Rickettsiales) comprises obligate intracellular Gram-negative bacteria of veterinary and public health importance. Six species and five types of strains genetically related are currently assigned to the genus Anaplasma including Anaplasma marginale, A. centrale, A. bovis, A. phagocytophilum, A. ovis and A. platys as classified species, and \"A. capra\", A. odocolei sp. nov.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29398602", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 181, 
          "text": "Human granulocytic anaplasmosis (HGA), an increasingly recognized febrile tick-borne illness, is caused by a gram-negative obligate intracellular bacterium Anaplasma phagocytophilum", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30217516", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the role of Acyl-Homoserine Lactone  in bacteria?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30352386", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29130184", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27896412", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12426339", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28887424", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26989738", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19464950"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Some bacteria use a class of chemical compounds called acyl-homoserine lactones (AHLs) as quorum sensing (QS) signals to coordinate their behavior at the population level.", 
        "A number of bacteria use a class of chemical compounds called acyl-homoserine lactones (AHLs) as quorum sensing (QS) signals to coordinate their behavior at the population level, including pathogens like Pseudomonas aeruginosa.", 
        "tructural analogues of acyl homoserine lactones with Quorum Sensing antagonist activity."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "5c979383ecadf2e73f000027", 
      "snippets": [
        {
          "offsetInBeginSection": 173, 
          "offsetInEndSection": 261, 
          "text": "tructural analogues of acyl homoserine lactones with Quorum Sensing antagonist activity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30352386", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 177, 
          "text": "A number of bacteria use a class of chemical compounds called acyl-homoserine lactones (AHLs) as quorum sensing (QS) signals to coordinate their behavior at the population level", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29130184", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 164, 
          "text": "OBJECTIVE\nBacterial colonization relies on communication between bacteria via so-called \"quorum-sensing molecules\", which include the acyl-homoserine lactone group.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27896412", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 175, 
          "text": "BACKGROUND\nN-Acyl homoserine lactone (AHL) is found to be the main component of quorum sensing (QS) in Gram-negative bacteria and plays an important role in biofilm formation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26989738", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 190, 
          "text": "Diverse Gram-negative bacteria communicate with each other by using diffusible N-acyl-homoserine lactone (AHL) signaling molecules to coordinate gene expression with cell population density.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19464950", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 192, 
          "text": "The genomes of many bacteria that participate in nitrogen cycling through the process of nitrification contain putative genes associated with acyl-homoserine lactone (AHL) quorum sensing (QS).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28887424", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 75, 
          "text": "Many proteobacteria use acyl-homoserine lactones as quorum-sensing signals.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12426339", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 152, 
          "text": "Bacterial colonization relies on communication between bacteria via so-called quorum-sensing molecules, which include the acyl-homoserine lactone group.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27896412", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List 3 indications for rituximab.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29606668", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28536935", 
        "http://www.ncbi.nlm.nih.gov/pubmed/30358861", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28185174", 
        "http://www.ncbi.nlm.nih.gov/pubmed/28633733", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23700188", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27603326", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23735074"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Rituximab  is used to treat rheumatoid arthritis as well as poly- and dermatomyositis, chronic lymphocytic leukemia, juvenile idiopathic arthritis, and Pemphigus foliaceus (PF)."
      ], 
      "exact_answer": [
        [
          "Rheumatoid arthritis"
        ], 
        [
          "Chronic Lymphocytic  Leukemia"
        ], 
        [
          "poly- and dermatomyositis"
        ], 
        [
          "juvenile idiopathic arthritis"
        ], 
        [
          "Pemphigus foliaceus"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "5c961281ecadf2e73f000021", 
      "snippets": [
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 272, 
          "text": "o assess clinical outcomes including imaging findings on computed tomography (CT), pulmonary function testing (PFT), and glucocorticoid (GC) use in patients with the antisynthetase syndrome (AS) and interstitial lung disease (ILD) treated with rituximab (RTX).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29606668", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1805, 
          "offsetInEndSection": 1892, 
          "text": " RIX is the preferred off-label biologic drug for poly- and dermatomyositis in Germany.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28536935", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 141, 
          "text": "Rituximab (RTX) may be a treatment option for children and young people with JIA, although it is not licensed for this indication", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30358861", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 24, 
          "offsetInEndSection": 98, 
          "text": " rituximab in children and young people with juvenile idiopathic arthritis", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30358861", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 79, 
          "offsetInEndSection": 285, 
          "text": "chronic lymphocytic leukemia (CLL) patients, including the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, phosphatidylinositol-3-kinase (PI3K) delta isoform inhibitor idelalisib combined with rituximab", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28185174", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 275, 
          "offsetInEndSection": 349, 
          "text": "rituximab's efficacy has been well-documented in adults with refractory PF", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28633733", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 59, 
          "text": "Rituximab in the management of juvenile pemphigus foliaceus", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28633733", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 167, 
          "text": "BACKGROUND\nRituximab is a chimeric, anti-CD20 monoclonal antibody registered for the treatment of B-cell malignancies and refractory rheumatoid arthritis in Australia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23735074", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 440, 
          "offsetInEndSection": 709, 
          "text": "Currently, rituximab is only FDA-approved for treatment of follicular and diffuse large B-cell non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia, granulomatosis with polyangiitis (formerly Wegener's granulomatosis) and microscopic polyangiitis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27603326", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1831, 
          "offsetInEndSection": 2116, 
          "text": "<AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">In our study, off-label rituximab was mainly used for the treatment of hematological, kidney, and systemic connective tissue disorders, and the response among our patient cohort was variable depending on the specific disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23700188", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is the crystal structure of Pim-1 available?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30033129", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25575657", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22926267", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23936194", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22339127", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16227208", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15808862"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes,\nThe crystal structures of Pim1 in apo form and bound with AMPPNP have been solved"
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5cb380b8ecadf2e73f00005d", 
      "snippets": [
        {
          "offsetInBeginSection": 505, 
          "offsetInEndSection": 673, 
          "text": "Recent crystallographic studies of Pim-1 have identified unique structural features but have not provided insight into how the kinase recognizes its target substrates. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16227208", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 351, 
          "offsetInEndSection": 454, 
          "text": "a co-crystal structure of lead molecule (HS38) in complex with DAPK3, a dual Pim/DAPK3 inhibitor (HS56)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30033129", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 265, 
          "offsetInEndSection": 425, 
          "text": "The crystal structure of this compound with PIM1 confirmed the predicted binding mode and protein-ligand interactions except those in the acidic ribose pocket. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25575657", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 422, 
          "offsetInEndSection": 690, 
          "text": "Using the determined X-ray crystal structure of PIM1 complexed to the compound 1-R as a control, we discuss the importance of including the protein flexibility inherent in the ensemble docking protocol, for the accuracy of the structure prediction of the bound state. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22926267", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 391, 
          "offsetInEndSection": 530, 
          "text": "Here, we describe the crystal structure of Pim1 in complex with a newly developed pyrido[4,3-d]pyrimidine-derivative inhibitor (SKI-O-068).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23936194", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 121, 
          "offsetInEndSection": 211, 
          "text": "Crystallographic and docking data analyses have been undertaken using inhibitor complexes ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22339127", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 378, 
          "offsetInEndSection": 459, 
          "text": "The crystal structures of Pim1 in apo form and bound with AMPPNP have been solved", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15808862", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Do tumour-associated macrophages have a prognostic role in gliomas?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28767130"
      ], 
      "triples": [], 
      "ideal_answer": [
        "M2-like TAMs hold an unfavourable prognostic value in high-grade gliomas and may contribute to a pro-tumourigenic microenvironment."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5c92159becadf2e73f000012", 
      "snippets": [
        {
          "offsetInBeginSection": 67, 
          "offsetInEndSection": 340, 
          "text": "Increasing evidence suggests that tumour-associated macrophages/microglia (TAMs) facilitate tumour progression by acquiring a M2-like phenotype. Our objective was to investigate the prognostic value of TAMs in gliomas using automated quantitative double immunofluorescence.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28767130", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1659, 
          "offsetInEndSection": 1932, 
          "text": "This is the first study to use automated quantitative immunofluorescence to determine the prognostic impact of TAMs. Our results suggest that M2-like TAMs hold an unfavourable prognostic value in high-grade gliomas and may contribute to a pro-tumourigenic microenvironment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28767130", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 941, 
          "offsetInEndSection": 1330, 
          "text": "Our data revealed that the amount of especially CD204+ TAMs increases with malignancy grade. In grade III-IV, high CD204 expression was associated with shorter survival, while high IBA-1 intensity correlated with a longer survival. In grade IV, CD204 showed independent prognostic value when adjusting for clinical data and the methylation status of O6-methylguanine-DNA methyltransferase.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28767130", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is TNF-\u03b1 an activator of pancreatic stellate cells?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24089530", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20689058"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes,\nTNF-\u03b1  is the prime factor responsible for the activation of pancreatic stellate cells."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5c9f0dabecadf2e73f00003b", 
      "snippets": [
        {
          "offsetInBeginSection": 825, 
          "offsetInEndSection": 910, 
          "text": "TNF-\u03b1 is the prime factor responsible for the activation of pancreatic stellate cells", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24089530", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 602, 
          "offsetInEndSection": 735, 
          "text": "Activated PSCs expressed IL-33 in the nucleus, and the expression was increased by IL-1\u03b2, TNF-\u03b1, PDGF-BB, and IFN-\u03b3, but not TGF-\u03b21. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20689058", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can mitochondria transfer from cell to cell?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29158129", 
        "http://www.ncbi.nlm.nih.gov/pubmed/29357914"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes,\nthe recently discovered phenomenon of mitochondrial transfer between mammalian cells has gained momentum since it was first described in cell culture systems more than a decade ago."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "5c9e738decadf2e73f000037", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 193, 
          "text": "Interest in the recently discovered phenomenon of mitochondrial transfer between mammalian cells has gained momentum since it was first described in cell culture systems more than a decade ago.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29158129", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2055, 
          "offsetInEndSection": 2160, 
          "text": "We show evidence that mitochondria transfer from Jurkat cells to MSCs, which is mediated by cell adhesion", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29357914", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1589, 
          "offsetInEndSection": 1721, 
          "text": "This process of mitochondria transfer is mediated by tunneling nanotubes, which are protrusions that extend from the cell membrane .", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29357914", 
          "endSection": "abstract"
        }
      ]
    }
  ]
}